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“Gentlemen, it is the microbes who will have the last word.” 
– Louis Pasteur (1822-1895) 
 
  
PREFACE 
My life so far has taken me on some rather big but interesting twists and turns. Since I was a 
young child I have always been very inquisitive. I remember distinctly asking my mother 
over and over again, “But why? But why? But why?!” Her exasperated answer would always 
finally be, “Because pigs don’t fly!” Of course that response did not satisfy me at all, and I 
continued to relentlessly question pretty much everything. As I grew older, I became particu-
larly interested in medicine. People would often ask me, “What do you want to be when you 
grow up?” and I would typically answer, “A veterinarian!” or “A doctor!” When I eventually 
entered nursing school instead, people did question my decision. Some, to my dismay, 
seemed disappointed that I chose not to pursue medicine anymore. Others encouraged me to 
follow my dreams and work hard to achieve my goals. Nursing did not just teach me numer-
ous technical skills, it also taught me about patience, empathy, kindness and compassion. My 
decision brought me to where I am today and for that I am grateful. 
My interest in infection prevention and control probably peaked when I got the opportunity to 
participate in a student exchange in Stockholm towards the end of my nursing studies. Over 
the course of four months I worked side by side with Swedish colleagues at Karolinska Uni-
versitetssjukhuset in Huddinge. It was during this time that I could witness stark differences 
between infection control practices in Sweden versus Malta and I was adamant that I wanted 
to be part of a change; to change infection prevention and control practices back home in 
Malta. Eventually, I was awarded a scholarship to pursue post-graduate education and moved 
to Stockholm to do my Master’s degree in Global Health at Karolinska Institutet where I was 
soon after employed as a research assistant. 
Realising the devastating consequences a world without antibiotics would cause, and that 
antibiotic use and resistance in Malta was among the highest in Europe, it stood to reason that 
building a project in my home country was a good place to start. So when I got the opportuni-
ty to devise my own doctoral project, I could not allow the chance slip me by. Starting from 
the ground up certainly posed its challenges but with a great deal of perseverance the project 
was up and running and I was eventually registered as a doctoral student. 
I sincerely hope that sharing my findings will help add another piece to the incredibly com-
plex puzzle that is antibiotic resistance. I hope that it will not only help raise a lot more 
awareness on the current antibiotic prescription practices in Malta, but that it will also inform 
future research and policy. 
Looking back, now that the project has drawn to an end, I realise that all the twists and turns 
that brought me to this place have been well worth it. I have grown and learnt so much 
throughout this entire process, and my inquisitive nature and critical mind has only intensi-
fied. Now that I have reached another crossroads in my life, I wonder what my next turn will 
be and where life will take me.  
ABSTRACT 
Background: Antibiotic resistance is a leading global public health problem and complex 
challenge. Although a multitude of factors affect its development, antibiotic use is a key 
driver. In fact, in Europe, a positive correlation between antibiotic use and resistance has 
been shown. The largest volumes of antibiotics are prescribed in the community setting and 
respiratory tract infections (RTIs) remain the most common diagnoses despite often being 
self-limiting. Malta has one of the highest antibiotic consumption rates in Europe with the 
top two reasons being sore throat and the flu. Since most antibiotics are obtained through a 
medical prescription, this suggests that antibiotics are overprescribed by doctors, and general 
practitioners (GPs) in particular are a suitable target group for interventions to improve anti-
biotic prescribing. However, prescribing decisions are often complex and influenced by nu-
merous interrelated factors. Therefore changing prescribing behaviour first necessitates an 
in-depth understanding of antibiotic prescribing practices and factors that impact this be-
haviour. To date, large knowledge gaps remain in Malta which makes the implementation of 
evidence-based interventions targeting prescribers challenging. 
Aim: The aim of this thesis, which forms part of a larger intervention project, was to explore 
GPs’ views on antibiotic use and resistance in Malta, and to gain a better understanding of 
their antibiotic prescribing patterns for RTIs including the factors that influence their pre-
scribing behaviour. 
Methods: Data were derived from two pre-intervention studies; one qualitative [Papers I & 
II] and one quantitative [Papers III & IV]. For the qualitative study, individual face-to-face 
interviews were held in 2014 with a quota sample of 20 GPs. Interviews were audio record-
ed and transcribed verbatim. Data were analysed iteratively using manifest and latent con-
tent analysis [Paper I] and phenomenography [Paper II]. The quantitative study was a re-
peated cross-sectional surveillance study for which 30 GPs and 3 GP trainees collected 
monthly data for all patients with an acute respiratory tract complaint during predetermined 
one week periods between May 2015 and April 2016. Descriptive statistics were used to 
examine patient, consultation and clinical characteristics, and to describe GPs’ prescribing 
patterns [Paper III]. In Paper IV, the association between GP-, practice- and consultation-
level factors, patient sociodemographic factors and patient health status factors, and antibi-
otic prescription (yes/no) was investigated using generalised estimating equations to esti-
mate population-averaged effects. 
Key findings: GPs’ provided an antibiotic prescription to 45.7% of cases, the majority of 
which (99.6%) were broad-spectrum. Almost all (84.3%) were for immediate use, whilst 
15.7% were delayed prescriptions. Through qualitative interviews five qualitatively different 
ways by which GPs perceived delayed antibiotic prescribing were described: (i) to maintain a 
good GP-patient relationship, retain patients and avoid doctor-shopping, (ii) to reach a 
compromise and provide treatment just in case, (iii) to provide the patient comfort and reas-
surance, (iv) to empower and educate patients, and limit antibiotic use, and (v) to retain GP 
  
responsibility by employing a wait-and-see approach. Surveillance data also revealed that 
GPs’ antibiotic prescribing is associated with a number of GP-, patient-, clinical- and con-
sultation-level factors. This was largely corroborated by qualitative evidence that showed 
that antibiotic prescribing is impacted not only by intrinsic GP factors but several other fac-
tors, including but not limited to, diagnostic uncertainty, patient demand, interaction with 
drug reps, availability of guidelines and community resistance data, and access to diagnostic 
testing. 
Conclusions: GPs’ antibiotic prescribing for RTIs in Malta is high. The abundant use of 
broad-spectrum antibiotics is of particular concern and indicates that antibiotics are not being 
used appropriately. A number of factors were found to impact GPs’ antibiotic prescribing 
behaviour. In order to improve this behaviour, targeted and coordinated implementation ac-
tivities must address barriers identified at all levels of the system and provide GPs with the 
necessary tools to alleviate diagnostic uncertainty. 
Trial registration number: NCT03218930 
Key words: antibiotic prescription, primary care, general practitioners, respiratory tract in-
fections, qualitative research, surveillance, barriers and facilitators, influencing factors, Malta  
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1 BACKGROUND 
1.1 THE GROWING THREAT OF ANTIMICROBIAL RESISTANCE 
1.1.1 Antimicrobials and antimicrobial resistance 
Antimicrobial drugs comprise a vast range of drugs, including antibiotics, antifungals, antivi-
rals, antimalarials and anthelmintics. These drugs can kill or inhibit the growth of specific 
microorganisms, including bacteria, fungi, viruses and parasites. Access to effective antimi-
crobial treatment is a prerequisite in medicine today. Unfortunately however, the hard-won 
gains achieved through the health-related Millennium Development Goals, are threatened by 
the increasing development of antimicrobial resistance.
1
 Antimicrobial resistance has been a 
growing public health threat for several decades
2
 and occurs when microorganisms counter-
act the exposure of antimicrobial drugs through a number of resistance mechanisms such as 
efflux, phosphorylation, hydrolysis, etc.
3
 The reduced efficacy of these drugs makes the 
treatment of infections challenging and expensive, sometimes impossible.
2
 This puts great 
strain on the sustainability of many public health interventions targeting communicable dis-
eases.
1
 If the necessary policies are not put into place to target antimicrobial resistance, it has 
been estimated that by 2050, antimicrobial resistance will cause ten million deaths worldwide 
per year, greater than the mortality attributed to cancer.
4
 This chapter will narrow its focus on 
antibiotic use and the imminent threat of antibiotic resistance, including strategies to contain 
its spread. 
1.1.2 Antibiotic resistance: a global and cross-sectoral crisis 
The discovery of antibiotics by Sir Alexander Fleming in 1928 revolutionised the field of 
medicine, moving it from a diagnosis- and prognosis-focused field, to an interventional one.
5
 
It gave us the opportunity to carry out procedures that before then had posed immense risks 
on morbidity and mortality. Surgery became safer, previously lethal infections became cura-
ble and certain life-saving procedures such as chemotherapy became possible. However, al-
ready in his Nobel Prize speech in 1945, Sir Alexander Fleming cautioned that bacteria could 
develop resistance towards these remarkable drugs.
2
 Indeed already in the 1950s, shortly after 
the introduction of penicillin in the 1940s, resistance to penicillin became a substantial clini-
cal problem.
5,6
 Although the development of antibiotic resistance is inevitable,
3
 as it is a natu-
ral evolutionary process for bacteria,
7
 their exposure to widespread antibiotic use exerts selec-
tive pressure on bacteria and accelerates resistance,
2
 as is evident in Figure 1. Figure 1 illus-
trates a timeline of how rapidly antibiotic-resistant bacteria were detected after antibiotics 
were introduced to the market.   
 2 
Figure 1. Timeline of the introduction of antibiotics and subsequent identification of antibiotic-resistant bacteria 
This image has been modified from Ventola (2015).6 Dates are based on early evidence of resistance in the literature except 
for pan-drug-resistant Acinetobacter and Pseudomonas where dates are based on reports of healthcare transmission or 
outbreaks. Please note that penicillin was in limited use before its widespread use in 1943. 
NOTE. PDR=pan-drug-resistant; R=resistant; XDR=extensively drug-resistant.  
Today, antibiotic resistance is one of the most pertinent and pressing global public health 
challenges of our time, that threatens modern medicine as we know it today and requires ur-
gent action.
2
 Whilst some improvements have been made, the problem is hardly subsiding.
8
 
Further exacerbating the problem is the fact that antibiotic resistance is a crisis that does not 
only concern human health, but spans across a number of sectors. Indeed, antibiotics have not 
only been misused in humans but also in the veterinary and food-production sectors. In addi-
tion, they have been released into the environment in an uncontrolled manner through, for 
example, inadequate treatment of sewage systems and pollution caused by the pharmaceutical 
industry.
7
 With the realisation that human, animal and environmental health are closely inter-
linked, the One Health approach was launched almost two decades ago
9
 and since then there 
have been many efforts to promote cross-sectoral and multidisciplinary collaboration to ad-
dress antibiotic resistance across all sectors.
10
 
Moreover, the rapid increase in antibiotic resistance worldwide pushed the issue to the fore-
front of top intergovernmental organisations’ agendas, including the European Commission, 
World Health Organization (WHO) and World Economic Forum. Already in 2001, the WHO 
had proposed a global strategy for the containment of antimicrobial resistance to slow down 
its emergence and decrease the spread of resistant microorganisms.
11
 Following the 68
th
 
World Health Assembly in May 2015, a global action plan on antimicrobial resistance was 
adopted, re-emphasising the need for adopting a One Health approach to ensure long-term, 
successful prevention and treatment of infectious diseases with safe and effective medicines 
that are used responsibly. It also set another objective, to have multi-sectoral national action 
plans prepared by Member States by the 2017 World Health Assembly.
1
 By March 2018, 100 
countries had drafted national action plans and 67 were in the planning phase.
12
 
  3 
1.2 IMPACT OF ANTIBIOTIC RESISTANCE ON HUMAN HEALTH 
Although the precise scale of this global problem and the impact of antibiotic resistance on 
human health and well-being is still largely unknown,
2
 antibiotic resistance due to common 
bacterial pathogens has reached alarming levels in many countries worldwide.
2
 Moreover, 
antibiotic development has declined markedly over the years, and many of the currently 
available treatment options are becoming increasingly ineffective in certain contexts.
2
 This 
has led prescribers to resort to stronger, more toxic and expensive drugs, often with devastat-
ing side effects on the patient.
6
 Unfortunately, reports of resistance towards last-line drugs 
like colistin, fosfomycin and ceftazidime-avibactam in the treatment of multidrug-resistant 
and extensively-drug-resistant Gram-negative bacteria are becoming more frequent.
13
 
Antibiotic-resistant infections pose considerable burden on patient outcomes and healthcare 
expenditure, both on a societal but also on an individual level.
2,14
 They lead to significantly 
longer hospital stays, increased morbidity and mortality,
6
 among a host of other negative con-
sequences. It has been found that hospital stays are prolonged by 6.4 to 12.7 days as a result 
of antibiotic-resistant infections, resulting in a total of eight million extra hospital days.
14
 In 
the United States, nearly two million patients develop healthcare-associated infections each 
year, resulting in 99,000 deaths that are largely a consequence of antibiotic-resistant patho-
gens.
15
 Furthermore, in 2006, it was reported that healthcare-associated sepsis and pneumonia 
caused the deaths of nearly 50,000 patients and cost the healthcare system more than US$8 
billion.
16
 
In a European Union (EU) report based on 2007 data from EU member states, Iceland and 
Norway, the burden of resistance in six multidrug-resistant bacteria was investigated and 
estimated to cost society approximately €1.5 billion per year in extra healthcare costs and 
productivity losses.
17
A more recent EU-/European Economic Area (EEA)-wide study esti-
mated the burden of antibiotic resistance in eight bacterial species and found that they ac-
counted for approximately 33,000 deaths and over 850,000 disability-adjusted life-years in 
2015.
18
 Patients younger than one and over 65 years were most afflicted, and a substantial 
proportion of the burden was estimated to have been caused by community-associated in-
fections. 
1.3 DRIVERS OF ANTIBIOTIC RESISTANCE 
It is evident that antibiotic resistance is a complex and multidimensional problem, driven by 
many interrelated factors.
2 
Antibiotic use, misuse and overuse, as well as unregulated con-
sumer access to antibiotics, are recognised key drivers of antibiotic resistance.
19–24
 Prolonged 
and low dose antibiotic therapy, and broad-spectrum antibiotics in particular, promote its de-
velopment.
25
 Antibiotic use in turn, is impacted by a multitude of factors, including 
knowledge, attitudes, perceptions, expectations, communication between prescribers and pa-
tients, time constraints, economic incentives, cultural factors, health system characteristics 
and regulations.
19,26–30
 The degree to which these factors impact antibiotic use in particular 
 4 
settings varies, and contextual factors must be considered when implementing antibiotic 
stewardship activities to improve antibiotic use. 
1.4 ANTIBIOTIC USE AND RESISTANCE IN EUROPE 
1.4.1 Public knowledge and awareness 
Knowledge on antibiotics varies depending on the context but remains below par. Indeed, a 
recent systematic review that included studies from all over the globe, found that 33.7% of 
people were not aware that antibiotics are used to treat bacterial infections and 53.9% did not 
know that antibiotics do not work against viruses. Whilst 59.4% were aware of antibiotic re-
sistance, 26.9% did not know that antibiotic misuse can aggravate the problem.
31
 In Europe 
specifically, the latest Eurobarometer report, for which the general public in 28 EU Member 
States were interviewed, showed that although there has been some improvement in the over-
all knowledge on antibiotics among Europeans since 2016, there is room for improvement.
32
 
The report demonstrated that only 25% of respondents correctly responded to the knowledge 
questions on antibiotics, with the highest knowledge scores achieved in Finland and Sweden, 
and the lowest in Latvia and Romania. Overall, only 43% of Europeans knew that antibiot-
ics are ineffective against viruses despite 85% being aware that unnecessary antibiotic use 
makes them become ineffective. Another European-wide study found that certain southern 
European countries like Malta and Italy, had significantly less appropriate attitudes, beliefs 
and knowledge compared to Swedish respondents.
33
 
It is evident that awareness on prudent antibiotic use among the general public must be im-
proved, particularly in countries with weaker knowledge and attitudes levels, by strengthen-
ing educational campaigns and encouraging doctors to provide patients with information.
31,34
 
Encouraging better antibiotic use through increased public knowledge and awareness could 
also have positive implications on actual and perceived patient demand,
29
 which has been 
shown to impact physicians’ antibiotic prescribing behaviour.35,36 
1.4.2 Impact of culture on antibiotic use 
In Europe, there is an evident geographical variation in antibiotic consumption and resistance. 
Antibiotics are used more in southern and eastern European regions.
37
 These regions tend to 
have higher antibiotic resistance levels than other parts of Europe with lower rates of antibi-
otic use.
38
 In fact, a correlation between outpatient antibiotic consumption and antibiotic re-
sistance has been shown in Europe,
39,40
 with a stronger correlation in southern European 
countries where antibiotic consumption rates are among the highest.
41
 
Arguably, cultural drivers have provided the best understanding of this geographical variation 
in antibiotic use in Europe.
26,42,43
 The most accepted approach used to analyse behavioural 
differences among countries is Geert Hofstede’s anthropological model of cultural dimen-
sions. The model describes how cultures vary along six fundamental dimensions: uncertainty 
avoidance, power distance, masculinity, individualism, long-term orientation and indul-
gence.
44
 Table 1 briefly describes each of these dimensions.  
  5 
The dimension that has been correlated most consistently with the overuse or inappropriate 
use of antibiotics is uncertainty avoidance.
26,30,46
 People in countries with high uncertainty 
avoidance scores tend to feel threatened and anxious by uncertain and ambiguous situations, 
and do not tolerate them well. As a result, doctors may feel compelled to act promptly rather 
than wait and see,
30
 prescribing antibiotics “just in case” when faced with uncertain clinical 
presentations.
47
 This provides a subconscious reassurance of certainty to both the patient and 
prescriber.
26
 In such contexts it is also more likely that wide-spectrum antibiotics are pre-
scribed and for longer durations.
47
 A positive correlation between power distance and antibi-
otic use has also been shown.
48
 In fact, Scandinavian countries like Sweden that have low 
rates of antibiotic use, score low in uncertainty avoidance but also power distance. Converse-
ly countries in the Mediterranean region, such as Malta, are characterised by high uncertainty 
avoidance and power distance scores.
47
 
1.4.3 Antibiotic prescription 
The largest volumes of antibiotics prescribed for systemic use in Europe are provided in the 
community setting,
49
 and despite most respiratory tract infections (RTIs) being self-limiting, 
they remain the most common indication.
39,50
 Although antibiotic prescription rates vary 
greatly by context and prescriber, studies have shown staggeringly high prescription rates for 
upper RTIs in outpatient settings, despite being seldom required.
39,51–56
 Indeed, antibiotics 
confer little benefit in most upper RTIs and the overall risk of developing complications by 
Table 1. Description of Geert Hofstede’s national cultural dimensions45 
National cultural dimensions Description 
Uncertainty avoidance 
The degree to which people within a society feel discomfort when faced 
with uncertain and ambiguous situations. Countries that exhibit high uncer-
tainty avoidance scores are intolerant of uncertainty and ambiguity whilst 
societies with weak scores have a more laid back attitude. 
Power distance 
The degree to which people with less power within a society accept and 
expect unequal distribution of power. In societies with high power distance 
scores, people accept hierarchies without question, whereas in societies 
with low power distance scores, people do their utmost to distribute power 
equitably and demand justification when power is not distributed equally. 
Masculinity versus femininity 
Masculine societies are typically more competitive. They provide material 
rewards for success, praise achievements, heroism and assertiveness. In 
feminine societies, people prefer cooperation, modesty, caring for the weak 
and quality of life. Such societies are usually more consensus-oriented. 
Individualism versus 
collectivism 
In individualistic societies, individuals are expected to take care of themselves 
and their immediate family. Conversely, in collectivist societies, individuals 
are also expected to care for extended family or members of a particular 
group of people. 
Long-term orientation versus 
short-term normative 
orientation 
Societies that score low in this dimension prefer to preserve traditions and 
norms and view societal change with suspicion. Those that score high are 
more pragmatic, encouraging thrift and modern education as they pave the 
way to the future. 
Indulgence versus restraint 
Indulgent societies allow deriving satisfaction from basic and natural human 
drives related to enjoying life and having fun. Restrained societies suppress 
this gratification by means of strict social norms. 
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withholding antibiotic treatment is small.
57–60
 Furthermore, antibiotic use exposes patients to 
unnecessary side effects and costs, and can have long-lasting impact on gut microbiota, which 
could propagate conditions such as obesity and allergies, particularly when used in infancy.
61
 
1.5 TURNING THE LENS ON MALTA 
In order to assist EU/EEA countries to outline and implement national action plans and strat-
egies to contain antimicrobial resistance and promote prudent antimicrobial use, the European 
Centre for Disease Prevention and Control (ECDC) conducts country visits upon invitation 
by national authorities. These visits are intended to discuss and assess the country’s situation 
regarding the prevention and control of antimicrobial resistance through appropriate antibi-
otic use and infection control.
62
 ECDC conducted a country visit to Malta, an archipelago 
situated in the centre of the Mediterranean Sea, in July 2017, where they assessed progress 
made since the first country visit in November 2009. Whilst good progress was observed in 
some areas such as a decrease in methicillin-resistant Staphylococcus aureus bacteraemia 
cases at the local public hospital (Mater Dei Hospital) and less access to oral antibiotics over-
the-counter, little difference was noted in other areas. Notably, it was reported that broad-
spectrum antibiotic use is still considerably high in the community.
62
 
At the time of ECDC’s country visit, the Maltese national action plan and strategy against 
antimicrobial resistance for 2017-2025 had been drafted but required further discussion with 
key stakeholders. Today, the national action plan for 2020-2025 has been drafted, discussed 
with key stakeholders (including the veterinary sector) and opened for public consultation. It 
is now awaiting final formal ministerial approval for its official launch. 
1.5.1 Public knowledge and awareness 
Although knowledge has increased slightly since the 2009 Eurobarometer survey,
32,63
 the 
general public still lacks adequate knowledge on appropriate antibiotic use, particularly when 
compared to other EU countries. In 2018, only 30% (EU28 average = 43%) of Maltese knew 
that antibiotics do not kill viruses and 46% (EU28 average = 66%) knew that antibiotics are 
ineffective against colds.
32
 In contrast, 92% (EU28 average = 85%) were aware that unneces-
sary antibiotic use makes them become ineffective. 
1.5.2 Community antibiotic consumption 
European Surveillance of Antimicrobial Consumption Network (ESAC-Net) reports have 
shown that community antibiotic consumption in Malta typically hovers around EU/EEA 
average but has not improved over the past decade,
37
 despite a reduction in over-the-counter 
sales.
64
 In contrast, Eurobarometer reports, which provide self-reported data on antibiotic 
consumption among EU Member States, portray a different picture, with antibiotic consump-
tion consistently among the highest in Europe. According to the 2013 report, 48% of the pop-
ulation consumed antibiotics during the previous year; the highest reported antibiotic con-
sumption at the time.
65
 Although the most recent report has shown a reduction to 42%, anti-
biotic consumption remains high.
32
 Furthermore, the top two reported indications were sore 
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throat (22%; EU28 average = 14%) and the flu (14%; EU28 average = 12%).
32
 Figure 2 
shows the trend in antibiotic consumption (using wholesale data) in the community between 
2009 and 2018 according to ESAC-Net reports. 
 
Figure 2. Antibiotic consumption (ATC group J01) in the community in Malta between 2009 and 2018, ex-
pressed in defined daily dose (DDD) per 1,000 inhabitants per day
66
 
1.5.3 Antibiotic prescribing in the community  
Although diagnosis-specific data on antibiotics prescribed in the community are unavailable, 
community antibiotic consumption data indicate that Maltese prescribers rely primarily on 
broad-spectrum antibiotics from four different antibiotic classes; penicillins with β-lactamase 
inhibitors, 2
nd
-generation cephalosporins, macrolides and fluoroquinolones.
64
 This is not jus-
tified neither by evidence-based international guidelines nor by local resistance patterns.
64
 A 
potential contributing factor to the unnecessary prescription of broad-spectrum agents is inac-
curate perceptions of resistance due to insufficient knowledge of the local epidemiology
39
 but 
also that narrow-spectrum antibiotics recommended by national antibiotic guidelines are re-
portedly unavailable from community pharmacies.
62
 Since it is recognised that broad-
spectrum antibiotics contribute to resistance more than narrow-spectrum antibiotics, the neg-
ligible prescription of narrow-spectrum antibiotics is concerning.
39
 
1.6 BEHAVIOUR CHANGE INTERVENTIONS 
In view of this complex problem and the fact that most antibiotics consumed in Malta are the 
result of a medical prescription,
32
 research on effective strategies to change prescribers’ 
knowledge and behaviour is needed to encourage appropriate antibiotic use.
39,67
 However, 
changing behaviour is complex, and whilst awareness campaigns and education are often 
recommended,
21,40
 interventions that aim to change behaviour are more likely to be effective. 
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Other J01 substances
Sulfonamides & trimethoprim (J01E)
Quinolone antibacterials (J01M)
Macrolides, lincosamides &
streptogramins (J01F)
Tetracyclines (J01A)
Other beta-lactam antibacterials
(J01D)
Beta-lactam antibacterials, penicillins
(J01C)
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1.6.1 Social and behaviour change communication: an ecological 
perspective to behaviour change 
Pivotal to the success of any behaviour change intervention is a thorough understanding of 
people and the various factors that impact their behaviour.
68
 With the realisation that an indi-
vidual’s behaviour is not only impacted by the individual him/herself but also the society and 
environment in which the individual is embedded, there has been a paradigm shift in how 
behaviour change researchers and programme implementers address behaviour change. In 
order to achieve sustainable behaviour change, there is a need to move beyond simply ad-
dressing individual behaviour through information and education, to tackling the problem 
from an ecological perspective, by understanding the interaction and interdependence of fac-
tors at all levels of the problem.
69,70
 
Social and behaviour change communication is a theory-based and research-driven process 
that builds upon behaviour change communication and is used to achieve behaviour change 
beyond just the individual level, by using targeted approaches that also impact the physical, 
socioeconomic and cultural environment.
69
 Social and behaviour change communication uses 
a socioecological model to identify critical areas in need of change in order to facilitate be-
haviour and address barriers to it. The socioecological model described by McLeroy et al.
71
 is 
a theory-based framework used to understand personal and environmental processes and in-
teractions that determine behaviour, and identify leverage points for change at five levels: 
intrapersonal, interpersonal, organisational, community and public policy. Such models can 
be used to address barriers and inform public health practice.
72
 Table 2 provides a description 
of each level of the socioecological model together with a few examples of factors that may 
have an impact on antibiotic prescription.  
Table 2. Description of factors that may impact behaviour at each level of the socioecological model 
27,71
 
Level Description 
Examples related to antibiotic 
prescription 
Intrapersonal 
Individual’s characteristics, including knowledge, 
attitudes, behaviour, self-efficacy, age, etc. 
Knowledge, attitudes and beliefs of 
the individual doctor 
Interpersonal 
Formal and informal social networks and support 
systems, including family, colleagues and friends 
Doctor-patient and doctor-
pharmacist relationships 
Organisational 
Social institutions with organisational characteristics 
and both formal and informal rules and regulations 
Antibiotic guidelines and regulations 
Community 
Relationships among organisations, institutions and 
informal networks within distinct boundaries  
Social networks and societal norms 
Public policy Local, state and national laws and policies 
Adherence to laws and regulations, 
e.g. prescription-only medicines 
Various strategies, theories and models can be used to address behaviour change at each level 
of the socioecological model. Since each level of influence may impact behaviour,
70
 the most 
successful approaches combine activities at all levels.
73
 However, these multi-level interven-
tions are rather complex and expensive to implement.
74
 Figure 3 depicts the five levels of 
the socioecological model grouped into three levels of change (i.e. the intrapersonal-, inter-
personal- and community-levels) with corresponding strategies and behavioural theories 
and models that can be used to better understand behaviour at each level of influence. 
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Figure 3. Key strategies for behaviour change at each level of the socioecological model and corresponding behavioural theories and models that can be used to understand behaviour
70,73
 
 10 
Behavioural theories and models like the theory of planned behaviour
75
 and stages of change 
model,
76
 are suitable approaches that can be used to better understand factors that influence 
prescribing practices. These methods have so far been underutilised in the development of 
interventions targeting antibiotic prescribing.
77
 In Europe and other high-income settings, 
several interventions and campaigns have attempted to use a behaviour change approach to 
promote appropriate antibiotic use, however, most did not consider the behavioural determi-
nants related to antibiotic use and prescription.
77
 Social marketing (SM) may provide a dif-
ferent insight on the development of behaviour change interventions targeting antibiotic use. 
1.6.2 Bridging theory and practice: social marketing and its role in public 
health interventions 
SM is an approach used to promote behaviour change by applying marketing theories and 
techniques to plan, implement and evaluate interventions to encourage voluntary behaviour 
change within a target audience.
70,78
 It combines concepts from commercial marketing and 
health education, and breaks them down into the following principles: measurable behaviour-
al objectives, “customer” or “consumer” orientation, segmentation (i.e. tailoring), competi-
tion (i.e. understanding benefits and barriers), exchange (i.e. emphasising the benefits of 
change), marketing mix (the “4Ps” of marketing – product, price, place and promotion), and 
long-term planning. It also takes context-specific issues into consideration in order to tailor 
interventions to one’s particular needs and increase the chance of success.78 When applied 
correctly, SM interventions can provide the right tools that are conducive to sustained behav-
iour change among targeted populations
67
 by identifying competing behaviours, and barriers 
and facilitators to change, but also offering optimal conditions for exchange, i.e. offering tar-
get audiences something they consider worthwhile in exchange for them changing their be-
haviour. Therefore, SM interventions should ensure that activities maximise benefits whilst 
minimising barriers that are considered important to the target group.
79
 Despite its potential, 
the utilisation of SM for the prevention and control of communicable diseases in Europe is 
still limited.
78
 
1.7 STRATEGIES TO COMBAT ANTIBIOTIC RESISTANCE 
A number of important strategies have been outlined in an effort to combat antibiotic re-
sistance. However, their application is impacted by several contextual issues that must be 
addressed for their successful uptake. Interventions that attempt to improve antibiotic pre-
scribing also tend to be more successful when they combine doctor, patient and public educa-
tion and when the design is multi-faceted.
50,80–83
 A recent systematic review that focused on 
antibiotic use for RTIs, found that multiple interventions that contained at least educational 
materials for doctors were most effective.
50
 The other element/s to be included will be highly 
dependent on the local context.
50
 Some of the suggested approaches are explained below. 
1.7.1 Surveillance 
The establishment of effective surveillance is critical for national and international efforts to 
contain antimicrobial resistance.
21
 There are currently large knowledge gaps on the distribu-
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tion and magnitude of antibiotic resistance in many regions of the world due to a lack of ade-
quate surveillance systems.
21
 Often, routine surveillance is performed on patients with severe 
infections, particularly those that are healthcare-related and for whom first-line antibiotic 
treatment was unsuccessful.
2
 Community-acquired infections are usually underrepresented 
among samples, leading to gaps in reporting among important patient groups.
2
 A more coor-
dinated and synchronised surveillance system to monitor antibiotic resistance at national, 
regional and global level, is urgently needed. This, together with the development of interna-
tionally-agreed standards for data collection and reporting across all sectors, i.e. human 
health, veterinary care and agriculture.
1
 Such data would help develop a better understanding 
of antibiotic resistance trends, monitor the situation to identify key areas that can be ad-
dressed in interventions to contain resistance, monitor the impact of interventions, determine 
optimal treatment options for patients, and inform public health policy.
2,21
 
At European level, ECDC coordinates and funds the European Antimicrobial Resistance Sur-
veillance Network (EARS-Net), a network of national surveillance systems that provide ref-
erence data on antimicrobial susceptibility of seven bacterial pathogens from 30 countries.
84
 
It also coordinates ESAC-Net, an interactive database that provides European reference data 
on antimicrobial consumption, both in the community and hospital sectors.
66
 Malta partici-
pates in both networks. However, whilst resistance and consumption data are routinely col-
lected within tertiary care, Malta can only provide wholesale data for the community; phar-
macies do not keep electronic records of prescriptions dispensed and therefore community 
antibiotic consumption data at prescription-level are unavailable.
64
 
1.7.2 Audit and feedback 
Prescription audit and feedback has been incorporated in many recent studies that provide 
data at an individual- or practice-level. However, there is limited evidence supporting the 
long-term impact of this strategy.
50,85
 In the Audit Project Odense model, Swedish general 
practitioners (GPs) recorded their consultations at two time points and received feedback in 
between. The medical audit resulted in a 10% decrease in antibiotic prescription within the 
intervention group.
86
 Providing individual prescribing feedback has also been shown to lead 
to improvements in guideline adherence.
87,88
 However, Gerber et al. found that although ini-
tial reductions in antibiotic use were seen following an educational seminar and quarterly 
individual feedback, these were not maintained and antibiotic use returned to baseline after 
one and a half years without audit and feedback.
89,90
 This stresses the importance of maintain-
ing audit and feedback if one is to sustain long-term improvements in antibiotic prescribing. 
1.7.3 Antibiotic prescribing guidelines 
Prescribing guidelines help clinicians translate the best evidence into practice. Although na-
tional antibiotic guidelines have been issued by several countries, few studies have assessed 
their impact on antibiotic prescribing behaviour.
85
 It has however been shown that guideline 
dissemination alone is not sufficient to reduce antibiotic prescribing rates.
50
 Studies from the 
United States have shown that despite some improvements in antibiotic selection, issuing 
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antibiotic guidelines had little effect on antibiotic prescribing for a number of upper RTIs.
91,92
 
A Belgian study showed that introducing guidelines led to short-term improvements in guide-
line-concordant antibiotic prescription, but that prescription returned to baseline levels after a 
17-month washout period.
93
 
1.7.4 Delayed antibiotic prescribing 
Delayed antibiotic prescribing is a method typically used by doctors to postpone or reduce 
antibiotic consumption. There are different ways by which doctors usually handle such pre-
scriptions. The doctor may, (i) provide an antibiotic prescription with the condition that the 
antibiotic should only be taken if symptoms persist or the patient’s condition worsens within 
a given time period (typically between 48 and 72 hours) (patient-led approach), (ii) post-date 
(forward-date) the prescription, meaning that the patient is unable to acquire the antibiotic 
before a specified date, or (iii) ask the patient to return to the clinic to either collect the pre-
scription or to be re-consulted by the doctor.
94
 Despite some national guidelines recommend-
ing delayed antibiotic prescribing, its application in clinical practice remains low
95,96
 and the 
motivation behind its use varies. Some use it to manage diagnostic uncertainty or avoid pa-
tient conflicts (particularly with those who pressure their doctors to prescribe), others use it as 
a tool for patient education and to promote shared decision-making.
96,97
 Some prescribers feel 
uncomfortable shifting clinical responsibility onto their patients and therefore dislike the ap-
proach.
96
 
1.7.5 Educational materials for patients 
Over the past decade, the use of patient information leaflets in primary care has been increas-
ing in popularity.
85
 Doctors can use them during consultations to help explain concepts to 
patients and patients may take them home to read later.
85
 Studies have shown that patient 
information booklets can not only help lower antibiotic prescribing rates,
98
 but also increase 
awareness on antibiotic use and give patients valuable information on, for example, the usual 
duration of different infections and how to recognise signs of severe illness.
99,100
 They can 
also increase knowledge and confidence among GPs, although some GPs report barriers such 
as lack of time and difficulty altering their consultation style.
99
 
1.7.6 Educational sessions for doctors 
A review of interventions targeting doctors to improve antibiotic use for RTIs showed that 
educational sessions, although arduous, appear to be more effective than audit and feedback, 
and circulation of written patient information.
50
 Educational sessions can include: information 
on the core principles of prudent antibiotic use, introduction to new tools (guidelines for ex-
ample), diagnostic skills training and sessions on patient communication.
85
 A few studies 
have shown that sessions incorporating these subject areas can lead to sustained improvement 
in antibiotic use that can last longer than two to four years.
101,102
 The degree of impact in oth-
er studies has generally been rather modest.
100,103–106
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1.8 RATIONALE FOR THIS THESIS 
Given that Malta has among the highest antibiotic consumers in Europe,
32,107
 targeting antibi-
otic overuse and misuse in this community is imperative. In Malta, most antibiotics for sys-
temic use are provided in the community setting. The top two reasons for which antibiotics 
are consumed are sore throat and the flu, for which antibiotics are largely unnecessary.
32
 Fur-
thermore, it has been shown that 96% of antibiotics consumed are the result of a medical pre-
scription.
32
 Since the Maltese consider doctors the most trustworthy source of information on 
antibiotics,
32
 they are important role models for their patients. GPs are therefore a key target 
group in this particular setting. 
Successful interventions must identify key local drivers of antibiotic prescribing and integrate 
incentives for behaviour change.
108
 However, we currently lack knowledge on what factors, 
particularly contextual ones, facilitators and barriers impact GPs’ antibiotic prescribing be-
haviour in Malta, particularly for RTIs. Moreover, no antibiotic prescribing data are available. 
As a result, we do not know the extent to which antibiotics are prescribed by GPs specifical-
ly. Neither are we able to determine their diagnosis-specific antibiotic prescribing rates. De-
veloping a more in-depth understanding of both GPs’ actual prescribing behaviour and the 
factors that influence their prescribing is pivotal to determine the appropriateness of antibiotic 
prescription and to develop suitable targeted interventions. 
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2 AIM AND OBJECTIVES 
2.1 AIM 
The overall aim of this thesis was to explore general practitioners’ views on antibiotic use and 
resistance in Malta, and to gain a better understanding of their antibiotic prescribing patterns 
for respiratory tract infections including the factors that influence their prescribing behaviour. 
The overarching goal was to identify and inform appropriate social marketing strategies in 
order to design, implement and evaluate a social marketing behaviour change intervention to 
improve general practitioners’ antibiotic prescribing practices in Malta. 
2.2 OBJECTIVES 
The specific objectives were to: 
a) explore general practitioners’ understanding of antibiotic use and resistance, and 
describe their perceived barriers and facilitators to prudent antibiotic prescribing for 
respiratory tract infections [Paper I] 
b) explore and describe the perceptions of delayed antibiotic prescription for respiratory 
tract infections among general practitioners [Paper II] 
c) determine the one year antibiotic prescribing patterns by general practitioners for 
acute respiratory tract complaints [Paper III] 
d) identify factors that influence general practitioners’ oral antibiotic prescribing for 
acute respiratory tract complaints [Paper IV] 
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3 METHODS 
This doctoral thesis forms part of a larger intervention project entitled the Maltese Antibiotic 
Stewardship Programme in the Community (MASPIC) for which a study protocol has been 
published (Appendix I).
109
 For the purpose of this thesis, only pre-intervention phase results 
are included. Nonetheless, a brief description of MASPIC is included here. 
A quasi-experimental multi-faceted SM intervention was implemented in Maltese primary 
care clinics to assess whether SM can influence GPs’ antibiotic prescribing for acute respira-
tory tract complaints (aRTCs). In order to design a tailored intervention, understanding key 
concerns, particularly contextual ones, that influence GPs’ antibiotic prescribing, is essential. 
Furthermore, for any SM intervention to be successful, an in-depth understanding of the tar-
get audience is required.
110
 Therefore the SM intervention was developed following a BE-
HAVE-based marketing plan
111
 (Figure 4). Through the BEHAVE framework critical ques-
tions could be addressed prior to selecting which interventions to implement, namely (i) who 
is the audience? (ii) what do we want them to do? and (iii) what factors influence their behav-
iour?
111
 Formative research is the best way to gain insight into the practices, views and atti-
tudes of target audiences and can be attained through, for example, focus group discussions 
and individual interviews. Therefore formative research findings from the pre-intervention 
phase could thereafter be used to inform subsequent studies and develop a SM intervention 
that addressed competing behaviours as well as barriers and facilitators to behaviour change. 
A short description of the intervention, which was delivered between October 2016 and 
March 2017, can be found in Appendix II. The intervention materials used have also been 
attached (Appendices III-V). 
3.1 THE MALTESE ARCHIPELAGO 
Malta is a Mediterranean archipelago that consists of five islands of which only three are in-
habited, Malta (the largest), Gozo and Comino.
112
 Malta is the smallest EU Member State in 
size (316 km
2
) and population, yet has the highest population density.
113
 The nation has two 
official languages, Maltese and English. Table 3 provides a few population and health indica-
tors for Malta in 2017 and 2018. 
Table 3. Population and health indicators for Malta in 2017 and 2018
113
 
Indicator 2017 2018 
Total population size 460,297 475,701 
Population aged 0-14 years (% of total) 14.1 13.9 
Population aged 65 years and over (% of total) 18.8 18.8 
Population density 1495.2 - 
Life expectancy (years) at birth (male/female) 80.2/84.6 - 
Total fertility rate 1.26 - 
Infant mortality rate 6.7 - 
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Promotion Place Price Product 
Study V 
To evaluate the interventions’ overall effect on GPs’ AB prescribing for aRTCs 
and 
To compare GPs’ stage-of-change and intention to prescribe ABs pre- and post-intervention 
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Study IV 
To design, develop and 
implement a tailored, 
context-specific, multi-
faceted intervention based 
on SM principles, to 
improve AB prescribing for 
aRTCs 
Step 7: Evaluate 
Step 6: Implement 
Step 5: Prototype and pre-test 
Step 4: Define the marketing mix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The project’s BEHAVE-based social marketing framework 
NOTE. AB – antibiotic; aRTC – acute respiratory tract compliant; DAP – delayed antibiotic prescription; GP – general 
practitioner; RTI – respiratory tract infection; SM – social marketing   
Study Ib 
To explore and 
describe GPs’ 
perceptions of DAP 
for RTIs 
Study Ia 
To explore GPs’ 
understanding of AB 
use and resistance, 
and describe their 
perceived barriers 
and facilitators to 
prudent prescribing 
To assess the effectiveness of a SM approach to 
improve GPs’ AB prescribing practices 
Problem definition 
High unnecessary AB use in 
Malta 
Target audience 
General practitioners 
Step 1: The bottom line 
 
To decrease unnecessary AB prescription for aRTCs 
Step 2: The behaviour we want to change 
 
AB prescribing for aRTCs 
Step 3: Develop a strategy 
Study IIIa 
To determine the one 
year AB prescribing 
patterns by GPs for 
aRTCs 
Study II 
To understand the 
AB prescription 
dynamic through 
different 
stakeholders; GPs, 
pharmacists and 
parents 
Study IIIb 
To identify factors 
that influence GPs’ 
oral AB prescribing 
for aRTCs 
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3.1.1 Health system organisation and financing 
Provision of health services, regulation and standards, and occupational health and safety are 
governed by the Ministry for Health with the Permanent Secretary as administrative head, 
accountable to the Prime Minister. S/he is responsible to support general policies and priori-
ties set by the government. The Chief Medical Officer is responsible for the Department for 
Policy in Health and is chief adviser to the Minister of Health on issues related to government 
health policies. The Department for Health Services is led by the Director General for Health 
Services who ensures that health services are delivered effectively and efficiently. The Super-
intendent of Public Health leads the Department for Health Regulation and is responsible for 
safeguarding public health, licensing, monitoring and inspecting health services provision in 
terms of quality and safety, and provides advice to the Minister of Health on public health 
issues.
112
 Figure 5 provides an overview of the organisation of Malta’s health system, rele-
vant to this thesis. 
Figure 5. Malta’s health system organisation. 
Adapted from Azzopardi-Muscat N. (2017)112 
Malta has an integrated health system organised at national level. It is primarily funded by 
taxation but is complemented by private financing.
114
 Health services are mainly provided by 
the public sector and are free-of-charge at point-of-care to Maltese residents covered by the 
Maltese Social Security Act. This usually covers all workers and their dependents, pension-
ers and persons on benefits due to their inability to work. It also provides care to irregular 
immigrants and alien employees with valid work permits.
112
 
Secondary and tertiary care are provided largely by specialised public hospitals although 
acute general services (ambulatory, inpatient and intensive care) are provided by a centrally-
located teaching hospital (Mater Dei Hospital).
112
 The private sector complements health ser-
vices provided by the public sector, particularly in primary care, and services are financed 
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through out-of-pocket payments and/or voluntary health insurance.
112
 No reimbursement sys-
tem exists, although a small percentage of the population are entitled to receive a restricted 
list of medicines, including antibiotics, directly from government pharmacies free-of-charge. 
3.1.2 Primary healthcare services and general practice 
As from 2003, qualified doctors who wish to work in primary care are expected to specialise 
in family medicine. However, GPs who began practising prior to 2003 were granted certified 
specialisation based on acquired experience and were therefore not required to undergo spe-
cialist training.
115
 In 2015, there were 83 registered GPs per 100,000 population.
112
 
It is estimated that approximately two-thirds of primary care is provided by GPs in the private 
sector.
112
 Patients are free to choose their own doctor and are therefore not registered to a 
particular GP. In the public sector patients are seen by whichever doctor is present on the day 
and do not generally develop a specific relationship with one GP; thus hindering continuity-
of-care. In the private sector, patients typically choose their own family doctor with whom 
they tend to have strong family ties. In fact, many private sector GPs often treat several gen-
erations within a family and it is still rather common for GPs to maintain close contact with 
regular patients throughout the duration of their illness. 
Public sector services are accessible mainly through nine public district healthcare centres in 
Malta and one in Gozo (Figure 6). Smaller local health clinics, staffed by their respective 
district healthcare centre, also provide services. Three of the healthcentres in Malta are 
open 24 hours a day to cater for patients requiring urgent care between 8pm and 8am. Gen-
eral practice services are provided on a walk-in basis and home visits are provided in urgent 
cases if the patient lacks transportation.
112
 Private sector GPs predominantly operate through 
solo practices from private clinics and/or clinics situated within retail pharmacies; few work 
in group practices.
112
 House visits are still in great demand and fairly common.
114
 Despite 
associated out-of-pocket costs, private GPs are generally favoured by patients due to better 
continuity-of-care and scheduling convenience.
112
 Finally, private sector GPs are not obliged 
to keep patient records, although some do so for personal use. 
Over the last three decades there have been many attempts to reform primary care to improve 
continuity-of-care in both the public and private sectors through patient registration. Howev-
er, these reforms have been met with opposition. Successful reforms have resulted in the ex-
pansion of service provision, infrastructure and equipment.
112
 Moreover, since 2012, GPs 
working in the private sector have been given increased access to public healthcare services 
and are now able to refer patients to the public sector for imaging and laboratory investiga-
tions. Laboratory tests are sent to and analysed at Mater Dei Hospital. Private sector GPs 
are also able to access electronic patient records for services provided in the public sector, 
including laboratory results and radiology reports.
112
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Figure 6. Map of Malta showing the ten district healthcare centres that provide primary healthcare services in 
the public sector. 
3.1.3 Regulation and governance of pharmaceuticals 
Pharmaceuticals can only be sold within licensed pharmacies in Malta.
112
 Antibiotics are pre-
scription-only medicines by law
116
 and more than 90% of antibiotics distributed are procured 
by private community pharmacies.
64
 Antibiotic prescriptions are considered invalid ten days 
after their date of issue
117
 and single-use prescriptions should be retained by the pharmacist 
upon dispensation.
118
 According to legislation, unless a prescriber specifically requests that 
an originator drug is to be dispensed, pharmacists can substitute the product so long as the 
product has the same active ingredient, dose and dosage form prescribed.
112
 
3.2 OVERVIEW OF THE PAPERS INCLUDED IN THIS THESIS 
To fulfil the aim and objectives of this thesis, a mixed methods approach was used. Table 4 
summarises the methods used in all four papers. 
Table 4. Overview of the papers included in this thesis 
Paper Main topic 
Study 
design 
Sampling and data 
collection 
Data analysis 
I 
Barriers and facilitators to 
prudent antibiotic prescribing 
Qualitative 
 Quota sample 
 Individual semi-
structured interviews 
Manifest and latent content 
analysis 
II 
Delayed antibiotic 
prescription 
Phenomenographic analysis 
III 
Antibiotic prescribing patterns 
for aRTCs 
Repeated 
cross-
sectional 
surveillance 
 Total population 
sample 
 One-year 
prospective 
surveillance 
Descriptive analysis 
IV 
Factors associated with 
antibiotic prescribing for 
aRTCs 
Population averaged 
models using generalised 
estimating equations 
NOTE. aRTC – acute respiratory tract complaint 
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3.3 INTERVIEWS WITH GENERAL PRACTITIONERS [PAPERS I & II] 
3.3.1 Interview guide development 
Following a thorough literature search and based on the co-authors’ expertise in the subject 
area, a semi-structured interview guide with prompts (Appendix VI) was developed in Eng-
lish and adapted to the local context. The guide was pilot tested with six GPs in March 2014 
and revised accordingly. Interview topics were broad and focused mainly on GPs’ views on: 
(i) antibiotic resistance and antibiotic use for RTIs, (ii) factors that influence their antibiotic 
prescribing, (iii) delayed antibiotic prescription (DAP), (iv) drug reps (also known as phar-
maceutical sales representatives) and the pharmaceutical industry, (v) use of diagnostic test-
ing for RTIs, and (vi) patient education. 
3.3.2 Study participants 
GPs registered on the Malta Medical Council’s 
Specialist Register were considered eligible for 
participation if they worked as GPs in the public 
and/or private healthcare sectors, irrespective of 
whether they worked part- or full-time. Registered 
GPs were called and invited to participate using 
quota sampling. In quota sampling, the researcher 
wants to ensure that the strata within the sample 
being investigated are proportional to those of the 
population under study, so that the sample of in-
terviewees is as representative of the population 
characteristics as possible.
119
 All eligible GPs to 
whom a phone number was available were listed 
and subsequently divided into strata based on the 
following characteristics and in the following or-
der: (i) years of experience as a GP, (ii) sex and 
(iii) locality of residence. A total of 30 GPs from within each stratum were contacted by 
phone in a stepwise fashion and invited to participate in this study. Four no longer worked as 
GPs and were considered ineligible whilst six declined participation. Ultimately 20 GPs par-
ticipated, of whom 14 were male. GPs’ age (years) ranged from 32 to 70 and their years’ of 
experience ranged from 7 to 45. Table 5 summarises the GPs’ characteristics. 
3.3.3 Data collection 
Individual interviews were conducted in August and September 2014 by the author of this 
thesis, a Maltese registered nurse who did not work clinically in Malta at the time of the in-
terviews and had no prior interaction with the participating GPs. The interviews were pri-
marily held in English, however respondents were free to reply in Maltese, without inhibiting 
the interview’s flow, as the interviewer was fluent in both languages. GPs often expressed 
themselves using a combination of the two languages. 
Table 5. Characteristics of general practitioners 
participating in interviews (n=20) 
  
n 
Sex 
male 14 
female 6 
Age (years) 
30-39 2 
40-49 4 
50-59 11 
60-69 2 
70-79 1 
Years of 
experience as a 
general 
practitioner 
<10 2 
10-19 3 
20-29 10 
30-39 3 
40-49 2 
Healthcare 
sector of practice 
public 4 
private 14 
both 2 
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GPs chose the time and place of the interview; often at their own workplace outside patient 
hours. Before the interview commenced, data on the GPs’ demographics, training and experi-
ence, and their healthcare sector of practice, were collected by the interviewer (Appendix 
VII). The face-to-face interviews lasted between 25 and 67 minutes (median = 40 minutes). 
Participants were encouraged to think out loud and speak openly about their views and expe-
riences, without being inhibited by the interviewer. GPs were also encouraged to provide 
concrete examples of patient encounters. Data were collected until no new information was 
gained and saturation was reached. Interviews were audio recorded and subsequently tran-
scribed verbatim by the interviewer. Maltese to English translation of responses was also per-
formed. Phrases that were hard to interpret or translate were discussed with a licensed Mal-
tese proof-reader, although this was seldom necessary. 
3.3.4 Data analyses 
Pilot interviews were excluded from all analyses. Therefore ultimately, 20 interview tran-
scripts were included in the analysis of both Papers I and II. 
3.3.4.1 Content analysis [Paper I] 
Interview transcripts were analysed iteratively and independently by the author of this thesis 
and another co-author using manifest and latent content analysis with an inductive ap-
proach.
120,121
 In manifest analysis, the researcher remains very close to the text and describes 
what the interviewees say whilst latent analysis involves deeper interpretation with the re-
searcher seeking to find the underlying meaning of the text.
122
 In brief, the two co-analysts 
read and re-read the interview transcripts (the unit of analysis) to familiarise themselves with 
the data. Meaning units were then extracted from the transcripts and subsequently condensed. 
Codes were derived from the condensed meaning units and similar codes grouped into sub-
categories. Sub-categories were subsequently sorted and merged into categories. The tenta-
tive categories were discussed between the co-analysts and revised. Finally the underlying 
meaning, or latent content, of the categories were abstracted into themes. Findings were dis-
cussed among all co-authors, until a consensus was reached. Table 6 presents a sample of the 
content analysis procedure employed to our data. 
3.3.4.2 Phenomenographic analysis [Paper II] 
In Paper II, data were analysed using a phenomenographic approach.
123
 Phenomenography is 
a qualitative research method that aims to empirically identify the qualitative variations of 
how people perceive, understand, conceptualise or experience a particular phenomenon.
124
 It 
was first developed to investigate learning in tertiary education but was later applied to other 
research fields, including understanding the various ways medical practitioners view different 
diseases, medical practice and antibiotic resistance.
125–130
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Table 6. Sample of the content analysis procedure used in Paper I 
Condensed meaning unit Code Sub-Category Category Sub-theme Theme 
If someone believed that I should 
have prescribed an antibiotic but I do 
not, he will go round the corner to 
another doctor. Doctor-shopping. That 
happens, I know it happens. I hope 
that it does not really happen in my 
practice but it happens yes. 
Doctor-shopping 
Pressure placed on GPs 
through patient demand 
and expectations 
General practitioners’ 
views on patient behaviour, 
knowledge and awareness, 
and their impact on general 
practitioners’ antibiotic 
prescribing 
Finding the right balance: 
addressing patient behaviour, 
knowledge and awareness 
through education and 
information provision 
General practitioners’ 
antibiotic prescribing 
decisions are complex and 
impacted by numerous 
barriers and facilitators at the 
intrapersonal, interpersonal, 
organisational, community 
and policy level 
There’s another problem when it 
comes to rapid tests in Malta, time. As 
GPs we work single-handedly. 
Sometimes we have to see long lists 
of people. If you do this test and that 
test you must have the infrastructure 
otherwise you would end up taking 
about half an hour to see one patient 
and in half an hour people start 
complaining. 
Rapid point-of-
care tests can be 
time consuming 
Views on rapid point-
of-care tests 
Access to and use of 
diagnostic testing in general 
practice 
Organisation and delivery of 
primary healthcare services, and 
the impact of public policy, 
regulation and guidelines on 
general practitioners’ antibiotic 
prescribing 
  23 
Every understanding of the phenomenon has two characteristics, the structural and referen-
tial.
131
 The structural aspect explains the individual’s focus of attention, or awareness, whilst 
the referential elucidates the meaning of the phenomenon to the individual, or how meaning 
is generated.
131
 Therefore a phenomenon is typically perceived in about three to seven al-
ternative ways, with distinct variations in focus and meaning.
128
 
Data were analysed iteratively by the author of this thesis and another co-author whilst brack-
eting their own preconceptions. Preliminary results were discussed with the remaining co-
authors and minor adjustments were made following their input. Finally, an outcome space 
was created. This graphical representation illustrates how different conceptions or perceptions 
relate to one another to form a phenomenon.
132
 Since some perceptions may be more com-
plex or include several aspects of a phenomenon, the outcome space is often presented in a 
hierarchy. A step-by-step summary of the data analysis process is outlined in Table 7. 
Table 7. The step-by-step phenomenographic analysis process used in Paper II 
1 Familiarisation 
Transcripts were read repeatedly and independently by two co-analysts to 
gain an overview of the material. 
2 
Compilation and 
condensation 
Every transcript was analysed individually by the co-analysts and the most 
significant statements where GPs described their views on and experiences 
with DAP were extracted and condensed. Transcripts were read with these 
questions in mind: What does this tell me about the way the GP perceives 
DAP? What does DAP mean to the GP and what is the focus? Next, 
important elements of the different conceptions were identified. 
3 
Comparison, grouping 
and preliminary 
description 
Similarities and dissimilarities between significant statements were identified, 
compared and grouped using preliminary labels. Preliminary descriptions of 
the various DAP perceptions were composed and labelled for every interview. 
4 
Formulation and 
labelling of different 
categories of 
description 
The different ways of understanding in all interviews were collated and 
compared, searching for similarities and differences. They were subsequently 
labelled and described as different categories of description. Preliminary 
categories of description were compared during discussions between the co-
analysts to determine whether the descriptions truly captured the variations in 
GPs’ views and experiences. 
5 
Final categories of 
description and 
outcome space 
Preliminary categories of description were presented to and discussed among 
all co-authors until consensus was reached and the final categories of 
description were determined. Lastly an outcome space was created. 
NOTE. DAP – delayed antibiotic prescription; GP – general practitioner 
3.4 ANTIBIOTIC PRESCRIBING SURVEILLANCE [PAPERS III & IV] 
3.4.1 Development of surveillance data collection form 
The surveillance data collection form was developed and tailored to the local context based 
on tools used in previous research
133,134
 and data collected from earlier qualitative studies 
within the MASPIC project. The form was piloted with eight GPs and checked for face valid-
ity, after which no major changes were made. The final form (Appendix VIII) included data 
on: (i) patient characteristics such as age, comorbidities and lifestyle factors, (ii) clinical char-
acteristics such as duration of symptoms and signs and symptoms, (iii) diagnostic testing, (iv) 
suspected aetiology and diagnosis, and (v) prescribed medicines. 
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3.4.2 Study participants 
All GPs registered on the Malta Medical Council’s Specialist Register and GP trainees were 
invited to partake. GPs were considered eligible if they were actively working as GPs full- or 
part-time. Of the 378 registered GPs and 34 trainees, 404 (98%) were invited. Eight were 
excluded as they were inactive or ineligible as they were already involved in the project. 
In November 2014, postal invitations with a six-week reminder were sent to registered GPs 
and trainees whose postal addresses were available online. In an attempt to target those who 
could not be reached by postal mail, e-mail invitations were sent out via local professional 
associations and a public invitation was distributed through a local medical professional net-
work called TheSynapse (www.thesynapse.eu). Invitations were also sent out through the 
Malta College of Family Doctors to target trainees enrolled in the specialist training pro-
gramme. Finally, phone calls were made to follow up with as many GPs as possible. 
Seventy registered GPs and trainees replied, of whom 35 agreed to participate. The remainder 
either declined participation (n=21) or were no longer practising GPs and were thus consid-
ered ineligible for participation (n=14). Before surveillance commenced, a further two regis-
tered GPs became ineligible; one transferred to non-clinical work and the other quit working 
as a GP. Ultimately, 30 GPs and 3 trainees participated (Table 8). GPs exhibited variation 
across various factors, including locality and sector of practice, years of practice as a GP, age 
and sex. Most GPs were male (n=24; 73%). Mean age (years) was 49±12 and mean years of 
practice as a GP was 23±11. 
Table 8. Characteristics of general practitioners (GPs) participating in antibiotic prescribing 
surveillance (n=33) 
  n 
Sex 
male 24 
female 9 
Age (years) 
28-39 7 
40-49 9 
50-59 14 
60-76 3 
Years of practice as a GP (n=32) 
<10 6 
10-19 5 
20-29 14 
≥30 7 
GP trainee 
no 30 
yes 3 
Type of employment 
part-time 11 
full-time 22 
Practice location 
public healthcentre clinic 13 
private clinic 14 
private pharmacy clinic 11 
Type of practice
*
 
group 16 
solo 17 
NOTE. GPs working in public healthcentre clinics were defined as group practice practitioners 
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3.4.3 Data collection 
During enrolment, GPs were asked to complete and submit a background information sheet, 
which included information on demographics, training and experience, and service delivery 
organisation (Appendix VII). They were also provided with a surveillance pack, which in-
cluded all the tools they required to complete the one-year surveillance study, including an 
instruction sheet, twelve pre-paid envelopes, data collection forms and tally charts. 
The study was carried out in both the public and private healthcare sectors. GPs personally 
registered all patients seen for an aRTC during twelve pre-determined surveillance weeks 
(one week/month with no substitutions) between May 2015 and April 2016. Forms were 
filled during first consultations with all patients suffering from any aRTC (lower- and upper-
RTIs, allergies and exacerbation of chronic obstructive pulmonary disease (COPD)/asthma/ 
bronchitis). Data on the total number of patients seen per day, irrespective of complaint, were 
also collected using the tally charts provided. In order to promote compliance, close commu-
nication was maintained with GPs throughout the surveillance year. Each surveillance week, 
GPs received three text messages; one prior to surveillance initiation to remind them to pre-
pare for data collection, another on the first surveillance day to remind them to initiate it and 
a third on the last surveillance day to remind them to conclude it and send completed sheets 
using pre-paid envelopes. GPs were also called at most four times throughout the year, to 
offer encouragement and address queries. Finally, GPs were e-mailed quarterly individual- 
and aggregate-level feedback reports on their prescribing patterns. 
3.4.4 Data analyses 
In total, data from 4,831 aRTC cases were recorded and input in Microsoft
®
 Excel 2010. Data 
were later transferred to Stata/IC
®
 13.1 for further data management and analyses. 
3.4.4.1 General patient eligibility criteria 
Only cases diagnosed with an aRTC were considered eligible for analysis. Cases had to have 
been consulting with the participating GP for the first time for that presenting complaint. Any 
follow-up visits recorded were automatically omitted from analysis. Cases where two or more 
aetiologies and/or diagnoses were provided were also excluded from analysis. 
3.4.4.2 General practitioners’ antibiotic prescribing patterns for acute respiratory tract 
complaints [Paper III] 
Following data cleaning, 190 cases (3.9%) were excluded from analysis using the general 
patient eligibility criteria outlined above, resulting in 4,641 aRTC cases (96.1%) eligible for 
analysis. Descriptive statistics were used to examine patient, consultation and clinical charac-
teristics, and to describe GPs’ antibiotic prescribing patterns. The WHO’s 2017 Anatomical 
Therapeutic Chemical (ATC) classification system was used to classify antibiotics.
135
 Antibi-
otic prescribing indicators were calculated using WHO’s manual on investigating drug use136 
and the ECDC, European Food Safety Authority and European Medicines Agency’s updated 
quality indicators for outpatient antibiotic use in Europe.
137
 To determine the extent of broad-
spectrum antibiotic prescription, the following ratio was used, ratio of broad-spectrum pen-
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icillins, cephalosporins, macrolides and fluoroquinolones (J01[CR+DC+DD+(F-
FA01)+MA]) to narrow-spectrum penicillins, cephalosporins and macrolides 
(J01[CA+CE+CF+DB+FA01]).
137 
3.4.4.3 Factors associated with general practitioners’ antibiotic prescribing for acute 
respiratory tract complaints [Paper IV] 
In addition to the general patient eligibility criteria defined above, all cases diagnosed with 
pneumonia and patients consulted over the phone were also excluded from this dataset. As a 
result, 313 aRTC cases (6.5%) were excluded from this analysis, reducing the final sample 
size to 4,518 (93.5%). 
Variables pertaining signs and symptoms, diagnostic testing, symptomatic treatment and oth-
er miscellaneous variables (Appendix VIII – Sections 6, 7, 11 and 12 respectively) that were 
not marked by GPs were assumed not present and analysed as absent, not tested or not pro-
vided. Analyses were conducted using complete case analysis. Descriptive statistics were 
calculated using frequencies and percentages, means and standard deviations (SDs), medians 
and interquartile ranges (IQRs) as appropriate. The outcome of interest was antibiotic pre-
scription (yes/no), defined as an oral antibiotic prescribed for an aRTC during an in-person 
consultation, irrespective of the number of antibiotics given. It included both immediate and 
delayed antibiotic prescriptions. It did not include ‘delayed instruction’, i.e. instruction to 
follow-up should symptoms persist or worsen. 
To control for clustering at GP level, potential predictors of antibiotic prescription were ana-
lysed using generalised estimating equations to estimate population-averaged effects. Fre-
quency distributions of explanatory variables of interest were calculated and univariable as-
sociations between each variable and antibiotic prescription were assessed using unadjusted 
odds ratios (ORs) and 95% confidence intervals (CIs). All continuous variables were catego-
rised since linearity to the outcome could not be assumed. Individual signs and symptoms 
variables were investigated if at least 5% of aRTC cases presented with that symptom. Multi-
variate Wald-type tests were performed on multi-level categorical variables to test the hy-
pothesis of the overall association. Finally, potential predictors were included in the multivar-
iable model if significant at p<0.2 at univariable level and excluded if there were collinearity 
issues. A predictor was kept in the multivariable model if it improved the model and its p-
value was <0.05. Ultimately 4,425 aRTC cases were included in the final multivariable mod-
el. 
3.5 ETHICAL CONSIDERATIONS 
Ethical approval for each study was sought from the University of Malta’s Research Ethics 
Committee. The ethical considerations are described below. 
3.5.1 Interviews with general practitioners [Papers I & II] 
Following the research ethics committee’s assessment, it was decided that since the study 
pertained medical professionals and no sensitive topics were to be discussed, it was exempt 
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from ethical approval. Despite this decision, standard ethical considerations were adhered to. 
During recruitment, participants were verbally informed about the study’s purpose and what 
their involvement would entail. Just before the interview, participants were given information 
letters outlining the study, its purpose, their role and the estimated duration of the interview. 
The letter also requested their permission to audio record the session. GPs were also given the 
opportunity to pose queries about the study. Informants were told that their participation is 
voluntary and that they were free to withdraw at any time and without justification or conse-
quences. No financial incentives were provided, however in return for their participation, GPs 
were offered certificates of participation that they could use to apply for continuing medical 
education credits through the Malta College of Family Doctors.  
GPs who agreed to participate were asked to sign an informed consent form, which both they 
and the researcher received a signed copy of, signed by both parties. Participants were each 
given individual codes that were kept in a separate file, accessible to only one member of the 
research team. Furthermore, all collected data were made confidential so as not to reveal 
GPs’ identities, and stored in a safe location. Signed consent forms were stored separately. 
There were no anticipated risks associated with participation, rather informants could have 
benefitted from being given the opportunity to reflect on their antibiotic prescribing practices 
and factors that may influence their prescribing decisions. 
3.5.2 Antibiotic prescribing surveillance [Papers III & IV] 
For this study, ethical approval was granted by the University of Malta’s Research Ethics 
Committee. GPs were sent information letters and consent forms to participate in this study, 
followed by one reminder. The information letter included information on the study’s pur-
pose, data collection method, a template of the data collection sheet and their role as partici-
pants. It informed them that they were free to withdraw from the study at any time without 
justification or consequences. It also informed them that in return for their participation they 
would be offered certificates of participation at the end of the surveillance year, based on the 
degree of their participation. This would allow them to apply for continuing medical educa-
tion credits through the Malta College of Family Doctors. Those interested were requested to 
submit their signed consent. 
During the one-year surveillance, doctors submitted surveillance sheets that were individually 
coded and confidential. Codes were stored in a separate file that could be accessed by only 
one member of the research team. Moreover, although the surveillance sheet included patient 
records, none of the information gathered risked compromising the patients’ identities since 
no names and/or identifiable data were collected. There were no major anticipated risks asso-
ciated with participation apart from the time GPs had to dedicate to filling in and submitting 
the sheets. However, all doctors were aware of this and the sheet was specifically designed to 
be very user-friendly. 
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4 KEY FINDINGS 
This chapter presents the key findings identified through Papers I-IV. The results are integrat-
ed below to highlight important aspects of each finding. 
4.1 ANTIBIOTIC PRESCRIBING PATTERNS 
Of the 4,641 aRTC cases that were eligible for analysis in Paper III, just over half were fe-
male (n=2,462; 53.1%) and median age was 29 years (IQR=12-49). The most frequently re-
ported signs and/or symptoms were sore throat (n=2,189; 47.2%), rhinorrhoea (n=1,701; 
36.7%), productive cough (n=1,481; 31.9%), non-productive cough (n=1,447; 31.2%) and 
fever (n=1,363; 29.4%). The top five most common diagnoses were common cold (n=1,536; 
33.1%), pharyngitis (n=743; 16.0%), bronchitis (n=570; 12.3%), tonsillitis (n=434; 9.4%) and 
sinusitis (n=305; 6.6%). 
Figure 7 shows the suspected aetiology by diagnosis as reported by participating GPs in Pa-
per III. Despite GPs in Paper I suggesting that the majority of upper RTIs (approximately 70-
90%) are viral in aetiology and would thus not necessitate an antibiotic, GPs in Paper III sus-
pected a viral aetiology in only 49.7% (n=2,307) aRTC cases. The rest were considered to 
have bacterial (n=1,280; 27.6%) or mixed (n=735; 15.8%) aetiologies. 
Figure 7. Suspected aetiology by diagnosis as reported by participating general practitioners 
 (a) Exacerbation of chronic obstructive pulmonary disease/asthma/bronchitis 
The antibiotic prescription rate, as indicated in Paper III, was rather high. In total, 45.7% 
(n=2,122) of aRTC cases received an antibiotic prescription. Of these, 84.3% (n=1,789) were 
for immediate use, the rest (n=333; 15.7%) were DAPs. The greatest proportion of antibiotic 
treatment was prescribed to cases with a suspected bacterial aetiology (n=1,213; 94.8%), fol-
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lowed by a suspected mixed aetiology (n=603; 82.0%). Nevertheless, 11.6% (n=268) of cases 
with a suspected viral infection were given an antibiotic prescription, the majority of which 
were delayed (n=231; 86.2%). In terms of diagnosis, the highest proportion of antibiotic pre-
scriptions were provided to patients diagnosed with tonsillitis (n=418; 96.3%), otitis media 
(n=111; 92.5%) and bronchitis (n=499; 87.5%). Similarly in Paper I, GPs reported that they 
typically prescribe antibiotics for tonsillar infections, otitis media, bronchitis, pneumonia, 
sinusitis (particularly if prolonged) and bacterial pharyngitis, reflecting their actual antibiotic 
prescribing behaviour as observed in Paper III. 
GPs prescribed broad-spectrum antibiotics in the majority of cases (99.6%). The most fre-
quently prescribed antibiotics were macrolides [J01FA] (n=757; 35.5%), followed by penicil-
lins with β-lactamase inhibitors [J01CR] (n=709; 33.2%) and 2nd-generation cephalosporins 
[J01DC] (n=302; 14.2%). Eleven cases (1%), diagnosed with pneumonia (n=4), bronchitis 
(n=4) and acute exacerbation of COPD/asthma/bronchitis (n=3), received combination treat-
ment i.e. two antibiotics from different classes. These combinations included penicillins with 
β-lactamase inhibitors together with macrolides [J01CR & J01FA] (n=7) or 2nd-generation 
cephalosporins together with macrolides [J01DC & J01FA] (n=4). Figure 8 below shows 
GPs’ antibiotic prescribing rate by diagnosis (Paper III). It also illustrates how GPs’ choice of 
antibiotic class varies by diagnosis. 
Figure 8. Antibiotic classes prescribed by general practitioners for each diagnosis, by antibiotic class 
(a) Exacerbation of chronic obstructive pulmonary disease/asthma/bronchitis 
NOTE. This figure includes delayed antibiotic prescriptions 
4.2 DELAYED ANTIBIOTIC PRESCRIPTION: PRACTICES AND PERCEPTIONS 
Results from Paper III showed that GPs do provide DAPs to patients with aRTCs. In fact, as 
mentioned earlier, of all patients who received an antibiotic prescription (n=2,122; 45.7%), 
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15.7% (n=333) were delayed. Through our findings we also showed that DAPs were provid-
ed mostly to patients with either a suspected viral (n=186; 58.3%) or mixed infection (n=102; 
32.0%). Through Paper II we were able to further understand GPs’ DAP practices by identi-
fying five qualitatively different ways that GPs perceive delayed antibiotic prescribing. These 
varying perceptions were labelled and described under five categories of description and are 
outlined in further detail below. 
4.2.1 “The Service Provider”: maintaining a good general practitioner-
patient relationship to retain patients and avoid doctor-shopping 
“Service providers” feared losing patients from their practice and mainly perceived delayed 
antibiotic prescribing as a strategy to maintain a good GP-patient relationship thereby ensur-
ing that patients return to the clinic. In this perception, GPs also focused on understanding 
why patients want immediate antibiotics; essentially to avoid a second visit for financial rea-
sons. Therefore GPs provided DAPs to avoid being perceived as avaricious by asking patients 
to return for a second visit. Some GPs also thought that providing a DAP can help manage 
patient expectations for antibiotics and avoid doctor-shopping, i.e. when patients visit several 
GPs for the same illness episode in order to obtain antibiotics. 
“Don't forget this is not a free clinic. People have to pay. I don't want to be seen that I'm abusing 
them by telling them to come back in two days' time for a prescription and charging them a second 
time.” (GP M) 
GPs either used a patient-led approach or a post-dated approach with a one to two day delay. 
Two GPs were sceptical towards a post-dated approach; they suspected that pharmacists 
would nonetheless dispense the antibiotic, rendering the method ineffective. One GP who 
preferred a patient-led approach requested that patients call for advice before buying the anti-
biotic. Another used post-dated prescriptions but collaborated closely with pharmacists in 
order to ensure that post-dated antibiotic prescriptions were not dispensed prematurely. 
4.2.2 “The Uncertainty Avoider”: reaching a compromise and providing 
treatment just in case 
DAP was perceived as a way of solving the “wait-and-see” dilemma by being careful and 
playing it safe when GPs were uncertain whether an immediate antibiotic prescription was 
warranted but suspected that antibiotic treatment could be needed within the coming days. 
GPs considered this a good compromise; ensuring that patients have access to treatment 
should they deteriorate within a few days. Ensuring that the patient will recover and not suf-
fer complications brought comfort to the GP. 
“I think it’s a good compromise… If I have a case where I think it’s not severe enough to warrant an-
tibiotics… I will give them a prescription and tell them that they should start it if they develop fever 
or feel worse after 48 hours…” (GP H) 
Only one GP post-dated DAPs, otherwise GPs used a patient-led approach. Of note, GPs of-
ten selectively provided DAPs to patients they knew and trusted. They would rather follow-
up with patients they considered untrustworthy or who they did not know well. To overcome 
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this challenge, one GP requested that patients call back before purchasing the antibiotic, 
providing an opportunity to reassess the situation and provide guidance over the phone. 
4.2.3 “The Comforter”: providing the patient comfort and reassurance 
Providing a DAP was perceived as a way of being considerate and understanding towards 
patients who are anxious and fear that their condition may worsen and require antibiotic ther-
apy. Similar to the “Uncertainty Avoiders”, GPs wanted to play it safe, however their ra-
tionale differed. GPs focused on being receptive towards patients’ needs and empathising 
with them. Therefore they provided DAPs to provide the patient comfort and reassurance 
knowing that they would have a prescription to fall back on should they deteriorate. 
“If you tell them [patients] I’m not going to prescribe you antibiotics… they freak out literally. So, I 
found that giving them a delayed prescription puts their mind at rest… they don’t need to come back 
again if these things happen.” (GP S) 
DAPs were only provided to patients GPs considered trustworthy, had a certain level of un-
derstanding, and/or were regular clients. In fact, GPs questioned whether delayed antibiotic 
prescribing is indeed best practice as they have no guarantee that patients will follow their 
advice. Trust was therefore a dominating decisive factor and GPs would rather ask patients 
who do not fulfil these criteria to follow-up in person than provide them with a DAP. Some 
GPs overcame this challenge by asking patients to call back for advice prior to purchasing the 
antibiotic. They also provided a thorough verbal explanation to the patient and a written note 
on the prescription to avoid the pharmacist dispensing the antibiotic prematurely. 
4.2.4 “The Conscientious Practitioner”: empowering and educating patients, 
and limiting antibiotic use 
“Conscientious Practitioners” were very concerned about antibiotic overuse in Malta and 
recognised antibiotic resistance as a threat. They showed a deeper understanding of delayed 
antibiotic prescribing and were avid users of this strategy. The DAP was perceived as a useful 
tool for educating and empowering patients, providing an opportunity to teach and persuade 
them that antibiotics are not always necessary. It was also perceived as a way of practising 
safer medicine by limiting antibiotic use when not required. GPs also reflected upon the im-
pact delayed antibiotic prescribing has on their own practice, how patients are positive to-
wards the approach and the resulting long-term societal gains. 
“I think it's [delayed antibiotic prescription] a useful tool, it's a tool especially for educating people as 
I said, you know they realise that the child got better without the antibiotic… it also gives the… pa-
tient power that he can be in charge… I think it's very educational… it's a good tool.” (GP B) 
Similar to other GPs, GPs in this category selectively provided DAPs to patients they trusted 
and to those who had a certain level of knowledge and awareness. One private sector GP col-
laborated with pharmacists to ensure that DAPs are dispensed appropriately and stressed the 
importance of communicating with patients when providing a DAP by keeping in touch in 
order to guide them when to purchase the antibiotic. 
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4.2.5 “The Holder of Professional Power”: retaining general practitioner 
responsibility by employing a wait-and-see approach 
GPs with this perception were very sure of themselves regarding when antibiotics should be 
prescribed and relied heavily on their training and expertise to determine whether a patient 
needed antibiotics. As the medical professional, they were of the opinion that it was their 
responsibility to ensure optimal patient outcomes. Therefore, in their perception, antibiotic 
prescribing decisions should not be transferred onto the patient, making delayed antibiotic 
prescribing an unsafe practice. To them, it was more important and justified to re-evaluate the 
patient in person should symptoms persist or deteriorate after the first consultation. 
“I usually don't do it [delay a prescription]. I usually caution the patient and tell him, look here, if you 
get a temperature, if the condition gets worse, just call again. Just to make sure that it's really need-
ed... I don't do it on purpose; I think it's justified… to revise the situation.” (GP C) 
Therefore GPs in this category did not practise delayed antibiotic prescribing and were not 
interested in utilising this strategy in the future. GPs shared the view that patients are general-
ly non-compliant to treatment and still maintain that they will not get better without antibiot-
ics. As a result, these GPs expressed that they would not trust patients to abide by their advice 
should they provide a DAP. 
4.2.6 The outcome space 
Figure 9. The outcome space  
The outcome space (Figure 9) illustrates how each category of description relates to another 
and has been split into DAP users and non-users. “Holders of Professional Power”, or non-
users, were unwilling to share decision-making and used a wait-and-see strategy instead. 
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“Conscientious Practitioners”, “Uncertainty Avoiders” and “Comforters” were selective DAP 
users. They used a wait-and-see approach whenever they considered a patient untrustworthy, 
unreliable, lacks certain levels of understanding and awareness, or perhaps they did not know 
the patient well-enough, reflecting similarities with the “Holders of Professional Power”. 
“Conscientious Practitioners” possessed a deeper level of self-reflection and higher degree of 
awareness of DAP as a tool for decreasing antibiotic use. In contrast, “Services Providers” 
were non-selective DAP users whose focus was on ensuring patient satisfaction and maintain-
ing a good GP-patient relationship, irrespective of who the patient is or his/her intentions. 
4.3 BARRIERS AND FACILITATORS TO ANTIBIOTIC PRESCRIBING AND 
FACTORS THAT INFLUENCE GENERAL PRACTITIONERS’ 
MANAGEMENT OF ACUTE RESPIRATORY TRACT COMPLAINTS 
In Paper I, our findings revealed that GPs’ antibiotic prescribing is impacted not only by their 
own knowledge, attitudes and awareness, but also by several external factors, including but 
not limited to patient demand and behaviour, information from drug reps, communication and 
collaboration with other healthcare professionals, availability of guidelines, access to diag-
nostic testing and ease of referral. It was evident that numerous barriers and facilitators influ-
ence GPs’ antibiotic prescribing which led to the construction of one overarching theme, 
namely, GPs' antibiotic prescribing decisions are complex and impacted by numerous barri-
ers and facilitators at the intrapersonal, interpersonal, organisational, community and policy 
level. 
In Papers III and IV, through actual antibiotic prescribing data and following multivariable 
analysis, we were able to corroborate some of these findings through a better understanding 
of how GPs manage patients with aRTCs and identifying significant factors associated with 
antibiotic prescription. We were also able to identify other factors that were not raised in Pa-
per I, including that female GPs were 2.3 times more likely to prescribe antibiotics (95% CI 
1.22-4.26). Furthermore, compared to younger GPs aged between 28 and 39 years, GPs aged 
50 to 59 (OR=2.1, 95% CI 1.19-3.77) or 60 years and older (OR=34.7, 95% CI 14.14-84.98) 
were more likely to prescribe antibiotics. Also, regular clients i.e. patients who tend to re-
consult with the same GP, were 1.3 times more likely to receive an antibiotic prescription 
(95% CI 1.05-1.66). 
In order to better illustrate and frame our findings, some of the factors identified to have an 
impact on GPs’ antibiotic prescribing are depicted in a socioecological model (Figure 10). 
The findings are described in further detail below through the four sub-themes identified in 
Paper I with results from Papers III and IV incorporated where relevant. 
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Figure 10. Overview of factors identified to have an impact on GPs’ antibiotic prescribing at all levels of the 
socioecological model 
4.3.1 General practitioners’ knowledge, awareness, views and experiences, 
and the resulting management of respiratory tract infections (sub-
theme I) 
Whilst many GPs viewed antibiotics as important and precious tools that should be used ap-
propriately and when recommended in guidelines, few of them seemed aware that effective 
antibiotic treatment options are running out. Even fewer acknowledged that antibiotics must 
be prescribed appropriately to halt the development of antibiotic resistance. However, most 
GPs were aware that antibiotic misuse accelerates antibiotic resistance and that consequently 
everybody is at fault – prescribers, pharmacists and the public.  
Through increased awareness, many GPs felt that antibiotic use is improving in Malta. None-
theless, many agreed that antibiotics are still misused, not just by prescribers but also by the 
general public who self-medicate through leftover use and over-the-counter acquisition of 
antibiotics, and are non-compliant to treatment. Although many GPs felt that over-the-counter 
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antibiotic dispensing has almost stopped, pharmacists were still blamed for contributing to the 
problem by dispensing antibiotics to patients without a prescription. Few GPs considered 
themselves high prescribers. However, many admitted to prescribing antibiotics without a 
focus of infection on occasion, particularly if in doubt or whenever they suspected that the 
patient may deteriorate. By doing so they safeguarded the patient and also themselves. 
Many GPs felt that infections are becoming more serious and sometimes harder to treat, indi-
cating that antibiotic resistance is on the rise in Malta. The rampant and repeated overuse and 
misuse of antibiotics, particularly for viral infections, and overuse of broad-spectrum antibiot-
ics, were considered important contributing factors. Additionally, marketing of specific anti-
biotics by drug reps was also considered a driver. Nevertheless, few GPs felt that antibiotic 
resistance directly impacts their practice. In fact, several GPs reported achieving good patient 
outcomes when prescribing antibiotics; to them antibiotic resistance was not yet a cause for 
concern. Meanwhile, some GPs mentioned that they were forced to prescribe higher antibi-
otic doses and more broad-spectrum antibiotics as a result of antibiotic resistance. 
Interestingly, although confirming whether non-response to antibiotic treatment was due to a 
viral infection or resistant pathogen was considered challenging by many GPs, several as-
sumed that non-response was a result of an infection caused by a resistant pathogen. Conse-
quently, GPs sometimes prescribed multiple antibiotic courses in an attempt to resolve an 
infection. Few GPs said that non-response to treatment could be the result of antibiotics being 
prescribed unnecessarily for a viral infection. GPs were more inclined to believe that even if 
an antibiotic was initially prescribed unnecessarily for a viral infection, subsequent non-
response to treatment indicated progression to a secondary bacterial infection which would 
justify the prescription of another antibiotic. 
“It’s very difficult to know whether an infection is resistant or whether they are non-responsive to 
treatment because they never needed antibiotics in the first place.” (GP B, female public sector GP 
with 25 years’ experience) 
Indeed, most GPs believed that viral infections commonly progress to secondary bacterial 
infections and that the elderly are particularly vulnerable to this. Therefore, many GPs low-
ered their antibiotic prescribing threshold for such patients. In fact, in Paper IV we showed 
that increasing patient age increased the likelihood of receiving an antibiotic prescription, 
with patients over 64 years being the most likely (OR=2.3, 95% CI 1.71-3.18). 
“There is a tendency for old, frail patients with viral infections to get secondary bacterial infections… 
It would be indicated that it is a viral infection but being an old patient, prescribing an antibiotic 
won’t do any harm.” (GP A, male private sector GP with 30 years’ experience) 
Determining the aetiology of RTIs, particularly lower RTIs, was considered challenging by 
some GPs. Some considered the time since onset of infection to determine the aetiology of an 
infection. GPs typically waited between two to five days for a viral infection to resolve and if 
not, they would often review the patient to decide whether to prescribe an antibiotic for a sus-
pected secondary bacterial infection. 
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GPs considered numerous other factors when deciding whether an RTI warrants an antibiotic 
prescription. According to GPs, they were more inclined to prescribe antibiotics to patients 
with high or intermittent fever, a sore throat with red and inflamed tonsils with pus, enlarged 
and tender lymph nodes, infected and tender sinuses, shortness of breath, crepitations, wheez-
ing, productive and persistent cough, purulent/greenish phlegm, chest pain and generalised 
malaise. Results from Paper IV identified similar signs and symptoms that significantly in-
creased the odds of a patient receiving an antibiotic prescription. More specifically, patients 
with tender cervical nodes (OR=2.2, 95% CI 1.57-3.05), fever >38.5
o
C (OR=2.6, 95% CI 
2.08-3.26), productive cough (OR=1.3, 95% CI 1.03-1.61) or otalgia (OR=1.3, 95% CI 1.01-
1.76) were more likely to receive an antibiotic. In contrast, patients with a non-productive 
cough (OR=0.3, 95% CI 0.26-0.41), sore throat (OR=0.6, 95% CI 0.53-0.78), rhinorrhoea 
(OR=0.3, 95% CI 0.23-0.36) or dyspnoea (OR=0.6, 95% CI 0.41-0.83), were less likely to be 
prescribed antibiotics. 
GPs also considered the patient’s smoking status, occupation and co-morbidities. They be-
lieved that smokers are more susceptible to bacterial infections and were therefore more like-
ly to prescribe antibiotics, particularly for suspected chest infections. In fact, smokers were 
1.4 times more likely to receive an antibiotic (95% CI 1.13-1.71) [Paper IV]. As aforemen-
tioned, patient age was an important factor that GPs considered when determining whether an 
antibiotic prescription is warranted. Several GPs avoided antibiotics in children since to their 
knowledge they are more likely to contract viral infections. On the other hand, they were 
more likely to prescribe prophylactic antibiotics to the elderly, even if absent of signs that 
would indicate a bacterial infection, as they wanted to avoid complications. Indeed GPs men-
tioned that patients with multiple co-morbidities, such as impaired renal and/or liver function, 
diabetes, heart disease, chronic chest infections, emphysema, asthma or COPD, were more 
likely to require antibiotics early. According to some GPs, these patients typically deteriorate 
quicker and often develop more complications and even pneumonia. 
“My threshold for prescribing antibiotics is much lower in patients with asthma and COPD, the rea-
son being that often when they get an infection it gets really bad, they get these infective exacerba-
tions, and if you don’t start treating immediately you’ll end up with a very bad situation.” (GP S, fe-
male public sector GP with 7 years’ experience) 
Finally, GPs mentioned that in order to improve patient compliance, they often adjusted their 
prescription to suit patients’ needs and preferences. GPs typically tailored antibiotic therapy 
(if necessary even changing antibiotic class) if the patient mentioned having discomforting 
side effects in the past such as thrush, nausea/vomiting or diarrhoea. They also considered the 
flavour of the antibiotic (particularly in children), dosage form and regimen. 
4.3.2 Finding the right balance: addressing patient behaviour, knowledge 
and awareness through education and information provision (sub-
theme II) 
According to some GPs, patient demand for antibiotics is decreasing in Malta. They attribut-
ed this to increasing awareness and more availability of information on the negative repercus-
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sions of antibiotic overuse. In fact, in Paper III only 76 patients (2%) actively requested anti-
biotics. Nonetheless, GPs expressed that patients still expect and demand antibiotics and put 
pressure on them to prescribe. A few postulated that expectations and demand are aggravated 
by easy access to services, which can lead to premature and unnecessary antibiotic prescrip-
tion. In fact, GPs reported that patients consult GPs upon onset of symptoms. Indeed most 
patients (n=3,397; 73.2%) consulted the GP within the first three symptomatic days [Paper 
III]. 
GPs reported that patients can sometimes exhibit aggressive attitudes towards them or return 
to blame them if they do not get better. They also threaten to consult other doctors who will 
give them what they want (doctor-shopping). Although most GPs expressed that they are 
largely unaffected by this behaviour, a few admitted that they do give in to patients on occa-
sion, even if they know that antibiotics are unnecessary. Whilst some believed that doing this 
is harmless, others deliberately prescribed shorter antibiotic courses, narrow-spectrum antibi-
otics or gave DAPs, in an effort to reduce harm. In Paper III we showed that of the 76 pa-
tients who requested antibiotics, 51 (67%) were given an antibiotic prescription, either for 
immediate or delayed use. In fact, according to findings from Paper IV, these patients were 
4.8 times more likely to be given an antibiotic prescription (95% CI 2.52-8.99). 
“Keeping your foot down is useless with people who keep insisting they want antibiotics. So I give 
them a very specific antibiotic, not broad-spectrum, so that I limit the damage as much as possible, 
and as short a course as possible with the lowest dose possible.” (GP R, male private sector GP with 
7 years’ experience) 
GPs felt that it is their responsibility to educate patients about the appropriate use of antibiot-
ics, and that by doing so they can also address misconceptions and improve compliance, 
which they reckoned will have a positive impact on demand in the long run. Nonetheless, 
according to GPs some patients were impossible to persuade. GPs found certain concepts, 
such as how antibiotic resistance develops, hard to explain to patients, particularly those less 
educated. A few GPs felt that introducing educational tools in the clinic, like images and 
charts, that can be used to explain concepts, are necessary and would be appreciated. 
4.3.3 Learning through interaction: the perceived importance of cooperation 
with other professionals (sub-theme III) 
Many GPs felt that it is important to engage in discussion with other medical doctors, particu-
larly when seeking advice. Whilst public sector GPs had such opportunities available to them, 
some private sector GPs felt isolated. Consequently, working closely with pharmacists was 
considered advantageous by several solo private practitioners who rented clinics within 
pharmacies. They used it to their advantage by discussing treatment plans and requesting ad-
vice when necessary. However, a few GPs mentioned that some pharmacists take advantage 
of this close professional relationship and make GPs feel obliged to prescribe medicines, de-
spite not always being necessary. 
GPs also interacted with drug reps rather frequently but had opposing views on them. Alt-
hough most were largely positive towards them, several complained that they visited too of-
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ten, which some regarded as a nuisance, mainly because they could make better use of their 
time consulting patients instead. However, to private GPs in particular, drug reps were 
viewed as important points of contact and a necessary educational resource, keeping them up-
to-date with the latest medical advancements. Drug reps provided them with much desired 
information on new drugs on the market, new technologies, resistance patterns and recent 
recommendations. However, not all GPs agreed that the information provided to them is 
credible, reliable and scientifically sound. Some believed that it is biased, and some suspected 
that it is sometimes fabricated. The fact that their recommendations are based on foreign evi-
dence and that drug reps claim that antibiotic resistance is on the rise and therefore antibiotic 
classes must be changed or doses increased, made them more cynical. 
“My views on medical reps in Malta are very mixed. On one hand they are a good source for infor-
mation; if you have any problems with medications, they are a very good source of information and 
they are pharmacists too. But on the other hand we have no way of verifying whether some of the 
claims they make are true or false.” (GP H, male private sector GP with 28 years’ experience) 
Not all GPs agreed that drug reps put pressure on them to prescribe antibiotics, and incentives 
were mostly mentioned as something that occurred in the past. Regardless, the majority of 
GPs insisted that they were uninfluenced by pressure from drug reps. A few disagreed, saying 
that regardless how hard one may try to remain uninfluenced by them, one’s antibiotic pre-
scribing choices are inevitably influenced by them. 
4.3.4 Organisation and delivery of primary healthcare services in Malta, and 
the impact of public policy, regulation and guidelines on general 
practitioners’ antibiotic prescribing (sub-theme IV) 
Access to community antibiotic prescribing guidelines and data on local antibiotic resistance 
rates varied among GPs. Public sector GPs said that guidelines can be found online but few 
private sector GPs were aware of this resource. Only two GPs actively looked up guidelines 
on occasion, whilst others only referred to guidelines as a last resort. However, many GPs 
thought that it is important to use guidelines to help support diagnoses and treatment, particu-
larly in complicated cases. To a few others, guidelines created more of a burden. A small 
number of GPs, particularly more experienced ones, valued experience more than guidelines. 
“Often when you reach my age, guidelines just make you laugh. If you want a frank and honest an-
swer, I do not abide by guidelines. Sometimes they are stupid.” (GP I, male private sector GP with 39 
years’ experience) 
GPs also felt that current data on antibiotic resistance rates are irrelevant to the Maltese 
community setting since they are based on in-patient data, and that antibiotic prescribing 
guidelines are not up-to-date or based on local evidence. This made GPs rather sceptical 
about their applicability in Maltese primary care and many wished for more relevant antibi-
otic prescribing guidelines. Several GPs believed that the lack of antibiotic resistance data 
and local guidelines to help inform prescribing decisions, leads to more cautious but some-
times more aggressive antibiotic prescription strategies. This, according to some GPs, was 
aggravated by the introduction of compulsory professional indemnity insurance in 2014. 
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One GP insisted that antibiotics are not abused in Malta but rather overprescribed uninten-
tionally since GPs are forced to prescribe blindly, without knowledge of what antibiotic to 
prescribe and the recommended dose. Consequently, GPs tend to play it safe, opting for the 
“usual” antibiotic, i.e. one they know is safe and effective, and provides good results. 
“We do not have any information on the current levels of antibiotic resistance in Malta… so we have 
to assume that whatever we’re prescribing is appropriate for the current levels of resistance both in 
terms of the medication and dose. We have no clue, no information at our fingertips, about minimum 
inhibitory concentrations or which antibiotics are effective for what we’re dealing with. So we some-
times have to make decisions which may not be appropriate.” (GP H, male private sector GP with 28 
years’ experience) 
Despite the lack of guidelines and uncertainty in antibiotic choices, GPs said that they seldom 
use diagnostic tests such as X-rays, C-reactive protein tests, throat swabs or sputum cultures, 
to help support their decisions, unless they considered the patient seriously ill. GPs in the 
public sector seemed more likely to use such services as they are more readily available to 
them. Usually however, many GPs prescribed antibiotics empirically first, occasionally pre-
scribing a second antibiotic if the first antibiotic does not successfully resolve the infection. 
This was later corroborated in our surveillance study [Paper III] where diagnostic tests were 
indeed rarely performed (n=133; 2.9%). 
“We prescribe antibiotics without carrying out bacteriological tests so we use our clinical judgement 
to try form an idea of what the underlying bacteriology is and treat it accordingly with the best anti-
biotic to match the infection.” (GP J, male private sector GP with 41 years’ experience) 
Very few GPs were familiar with rapid point-of-care tests (POCTs) for RTIs, and according 
to most they are unavailable in Malta. Consequently, almost all GPs had never used or con-
sidered using them. Only one GP used rapid strep tests regularly and intended to invest more 
in them to reduce antibiotic use. To him, rapid POCTs were good educational tools that allow 
patients to better understand their condition and treatment plan. Several GPs were positive 
towards introducing rapid POCTs in general practice. They believed that rapid POCTs could 
help guide antibiotic prescription, particularly when the aetiology is unclear, and consequent-
ly decrease antibiotic overuse. Some also felt that they could help negotiate a care plan with 
the patient. Others asserted that even if introduced, they were unlikely to use them. To them, 
their own clinical assessment and experience was sufficient to make a correct diagnosis. 
“I would use diagnostic tests if they were available. They would absolutely be very helpful. You can 
make your case for antibiotics. You can explain to patients that the results are positive which means 
you have a bacterial infection and what they need. It can be used to persuade the patient rather than 
basing it just on my clinical impression.” (GP M, male public and private sector GP with 23 years’ 
experience) 
The main barriers to diagnostic testing (both rapid POCTs and other diagnostic tests) were 
time and lack of access. Whilst certain diagnostic facilities are readily available to GPs work-
ing in the public sector, private sector GPs must refer patients for most services. They consid-
ered this time-consuming and burdensome, particularly since it takes times for results to be 
issued. Occasionally they do not receive the results at all. GPs would therefore rather pre-
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scribe antibiotics without knowing whether they are truly warranted, than wait and risk that in 
the meantime the patient develops complications. Another deterrent to diagnostic testing was 
cost. In private practice, where patients pay for services out-of-pocket, a few GPs said that it 
is illogical to charge for testing if the resulting cost is more than the consultation and an anti-
biotic prescription combined. They suspected that if they charge for such services, that they 
would lose patients to other GPs. 
“Near patient testing is an excellent idea but it takes time. I’ve tried it but it takes time. We do not 
have the luxury of having staff who can do it so we have to charge for our time. Although it is a good 
idea and although I have tried to integrate it, some take more time than others. It’s not practical.” (GP 
H, male private sector GP with 28 years’ experience) 
GPs encountered similar problems with feedback among the primary, secondary and tertiary 
sectors when referring patients, not just for diagnostic testing, but also other services. Accord-
ing to GPs, the lack of IT infrastructure resulted in poor feedback from specialists and hospi-
tals regarding referred cases, causing time delays and impacting continuity-of-care. 
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5 DISCUSSION 
Our studies have, for the first time, shed light on GPs’ understanding of antibiotic use and 
resistance in Malta as well as their actual prescribing practices for aRTCs. We also further 
identified key barriers and facilitators that can be addressed when implementing strategies to 
contain antibiotic resistance and promote better antibiotic use in Malta. This is the one of the 
first crucial steps in SM; gaining a good understanding of one’s target audience (also known 
as customer or consumer orientation) and the competition, i.e. barriers that discourage the 
adoption of preferred behaviours.
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5.1 GENERAL PRACTITIONERS’ VIEWS ON ANTIBIOTICS AND ANTIBIOTIC 
RESISTANCE 
Many GPs’ were aware that antibiotic misuse promotes resistance, and that it is therefore 
important to use antibiotics appropriately. They believed that everyone (prescribers, the pub-
lic and pharmacists alike) must take responsibility for the problem. Whilst they felt that 
awareness among all stakeholders is increasing, they nonetheless felt that self-medication, 
non-compliance to treatment, leftover antibiotic use and over-the-counter dispensing remain a 
problem. According to reports however, over-the-counter dispensing is low in Malta, and 
most people rather acquire their prescription through a medical professional.
32,116
 Unfortu-
nately, there are currently only a few authorised leftover medication disposal sites in Malta,
62
 
which could explain why leftover antibiotic use and self-medication remain a problem. 
Moreover, antibiotic packs sometimes contain more antibiotic doses than necessary. Since it 
is illegal to split packs, patients may end up with leftover antibiotics at home, with few plac-
es to dispose of them safely, which further promotes the misuse of leftover antibiotics.
62
 
Antibiotic resistance was considered an increasingly important problem. However, similar to 
views shared by GPs in other studies,
138,139
 few felt that it directly impacts their day-to-day 
practice. Consequently, some did not consider antibiotic resistance to be a cause for concern 
in Malta as of yet. Those who did believe that antibiotic resistance is getting worse locally 
attributed it to the repeated overuse and misuse of antibiotics, particularly broad-spectrum, 
and promotion of specific antibiotic classes by drug reps. 
It is important to be mindful that GPs’ heightened awareness on antibiotic resistance may 
have a negative impact on their antibiotic prescribing behaviour. It could lead GPs to practise 
more cautious prescribing behaviour such as using broad-spectrum antibiotics more freely.
139
 
It could also lead to more aggressive antibiotic prescription. In fact, a few GPs said that they 
sometimes provided combination antibiotic therapy to minimise the risk of promoting antibi-
otic resistance. Others attributed non-response to treatment to antibiotic resistance and conse-
quently prescribed multiple antibiotic courses on occasion. 
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5.2 ANTIBIOTIC PRESCRIBING PATTERNS 
5.2.1 Prescription of broad-spectrum antibiotics 
In Paper III it was shown that 45.7% of aRTC cases were given an antibiotic prescription by a 
GP, closely reflecting the findings of the 2016 Eurobarometer report where 48% of Maltese 
participants reported taking an antibiotic during the past 12 months.
107
 At the time, this was 
the highest reported antibiotic consumption rate in the EU/EAA, and although it has since 
decreased to 42%,
32
 it remains high. A comparable antibiotic prescription rate of 46.8% was 
reported in (southern) Italy,
140
 a Mediterranean country with similar sociocultural traits.
26
 
Earlier reports have shown that prescription of narrow-spectrum antibiotics is negligible in 
Malta,
37,62,64
 dissimilar to Sweden for example, where narrow-spectrum penicillins are the 
most frequently prescribed antibiotics in outpatient care.
141
 Unsurprisingly, broad-spectrum 
antibiotic use was extremely high in our study [Paper III] at 99.6% and is similar to other 
southern European countries such as Spain and Greece.
142,143
 According to the latest ECDC 
report on antimicrobial consumption,
37
 Malta has had the highest ratio of broad- to narrow-
spectrum antibiotic use in the EU/EAA for the past decade and it remains high at 24.0 
(EU/EAA average = 2.9). In our study we observed an even higher ratio of 33.2. The fact that 
our data were limited to aRTC cases only, could explain this difference and suggests that 
aRTCs contribute greatly to the prescription of broad-spectrum antibiotics in Malta. Since 
broad-spectrum antibiotic use favours the development of antibiotic resistance,
25,64
 their 
widespread use is of great concern. 
Penicillins with β-lactamase inhibitors, 2nd-generation cephalosporins, broad-spectrum mac-
rolides and fluoroquinolones, made up 90% of all antibiotics prescribed [Paper III]. These 
antibiotics are major drivers of resistance.
64
 Previous reports have shown that broad-spectrum 
penicillins with β-lactamase inhibitors are the most commonly prescribed antibiotic in Mal-
ta.
37,49,64
 In our study [Paper III] however, GPs showed a preference towards macrolides, sim-
ilar to prescribers in Greece and the United States.
143,144
 This finding raises concerns since the 
rates of Streptococcus pneumoniae invasive isolates resistant to macrolides are rather high in 
southern European countries like Malta.
38
 Another concern is the increasing rates of Esche-
richia coli resistant to fluoroquinolones in Malta. Consequently, efforts need to be made to 
decrease the prescription of broad-spectrum antibiotics for respiratory pathogens, particularly 
macrolides and fluoroquinolones. 
5.2.2 Factors associated with antibiotic prescription 
5.2.2.1 General practitioners’ age and years of practice 
Older GPs were more likely to prescribe antibiotics [Paper IV]. Age reflects GPs’ years of 
experience and it has similarly been shown that GPs with more years of practice are more 
likely to provide antibiotic prescriptions.
145
 As aforementioned, family medicine was not rec-
ognised as a medical specialisation in Malta until 2004, after which doctors were obliged to 
undergo specialist training in family medicine. However, those doctors who practised as GPs 
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prior to November 2003 were exempt from specialist training.
115
 Consequently, the fact that 
younger GPs had recently undergone specialist training could explain why they were lower 
antibiotic prescribers than their older, more experienced, peers. It is likely that older GPs en-
gage in habitual prescribing behaviour and may require updated access to the latest antibiotic 
prescription guidelines as well as opportunities to participate in refresher courses on the topic. 
5.2.2.2 Patient and clinical factors 
Verbal reports from GPs [Paper I] as well as their actual prescribing behaviour [Paper IV] 
indicate that GPs in Malta are more likely to prescribe antibiotics to the elderly, and less like-
ly to prescribe to children. This is consistent with similar studies where antibiotic treatment 
increased with patient age.
146–150
 Interestingly, in England/Wales and Sweden, antibiotic 
treatment rates were high among both the elderly and children,
151,152
 whilst in Norway, pa-
tients aged over 80 years were the least likely to receive an antibiotic prescription.
153
 The 
prescribing behaviour of Maltese GPs reflects their beliefs that children are often afflicted by 
viral infections, and that the elderly are more susceptible to secondary bacterial infections and 
to deteriorate quicker as a result of complications. The elderly are also more likely to suffer 
from multiple co-morbidities like impaired renal and/or liver function, diabetes, heart disease, 
chronic chest infections, emphysema, asthma or COPD, which according to GPs, would low-
er their antibiotic prescribing threshold [Paper I], although this association was not found in 
Paper IV. 
Being a current smoker has also been found to be associated with antibiotic prescription,
154–
156
 similar to our findings. Although there is no evidence that antibiotics confer better clinical 
outcomes in smokers,
155
 GPs still believed that smokers are more likely to deteriorate without 
antibiotics [Paper I] and were in fact more likely to prescribe them [Paper IV].  
A multi-country European study showed that GPs do not only consider risk factors like co-
morbidities and age, but also signs and symptoms that they believe warrant an antibiotic pre-
scription.
157
 Indeed studies have shown that GPs consider a wide range of clinical factors 
when deciding whether to prescribe an antibiotic.
29
 This is also evident in Papers I and IV. 
GPs in Paper I mentioned that they were more likely to prescribe antibiotics to patients with a 
number of different signs and/or symptoms, including enlarged and tender lymph nodes, fe-
ver, productive cough and sore throat with red, swollen tonsils and pus. In fact, in Study IV a 
number of similar factors that were independent predictors of antibiotic prescribing were 
identified. It is likely that GPs believe that these factors suggest a bacterial infection, or are an 
early warning sign of more severe illness which could explain why their antibiotic prescribing 
threshold decreases. 
5.2.3 Diagnosis-specific antibiotic prescription 
The most common indications that led GPs to prescribe antibiotics were acute tonsillitis, oti-
tis media, bronchitis and sinusitis [Paper III], similar to Belgian prescribers.
158
 More specifi-
cally, over 65% of patients with these diagnoses were prescribed antibiotics. In fact, GPs dis-
closed that they were more likely to prescribe antibiotics to patients with tonsillar infections, 
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otitis media, bronchitis and sinusitis, but also with pneumonia and pharyngitis [Paper I]. Sim-
ilar research carried out in Spain and Sweden also found comparably high antibiotic prescrip-
tion rates for tonsillitis, otitis media and sinusitis, however lower rates for bronchitis.
142,158
 
There is however limited evidence to justify antibiotic prescription for uncomplicated acute 
bronchitis and sinusitis.
159–161
 Despite this, acute bronchitis in adults is one of the most com-
mon causes of inappropriate antibiotic prescribing.
162
 
Notably, GPs not only reported a high variation in choice of antibiotic class by diagnosis but 
also suspected aetiology (by diagnosis) [Paper III]. Although many GPs believed that approx-
imately 70-90% of upper RTIs are viral [Paper I], their behaviour suggests that GPs overes-
timate the degree to which certain RTIs are bacterial. Indeed, determining the aetiology of 
RTIs was considered challenging by many GPs [Paper I]. 
5.3 DIAGNOSTIC UNCERTAINTY 
Diagnostic uncertainty was a major drawback to appropriate antibiotic prescription according 
to GPs [Paper I], and has often been reported to be a barrier,
163
 correlated with antibiotic mis-
use and overuse.
26,30,46
 The inability to determine the aetiology of infections due to lack of 
access to testing, relevant reports and guidelines, was an important issue raised by GPs and 
could partly explain their antibiotic prescribing behaviour observed in Papers III and IV, and 
their attitudes towards antibiotics. In fact, GPs often expressed [Paper I] that they found it 
hard to differentiate between viral and bacterial infections. As a result, they sometimes pre-
scribed antibiotics “just in case” out of fear of negative repercussions, including patient com-
plications and legal consequences, despite there being no added benefit of prescribing antibi-
otics prophylactically in viral infections.
164
 
Several GPs also believed that non-response to antibiotic treatment is the result of an antibi-
otic-resistant infection or secondary bacterial infection. To many, viral infections commonly 
progress to secondary bacterial infections. Although possible for viral infections to progress 
to secondary bacterial infections,
165
 given GPs’ antibiotic prescribing patterns, it appears to 
be over-estimated, particularly since patients tend to consult GPs upon onset of symptoms, 
often within the first three symptomatic days [Paper III]. Moreover, GPs reported typically 
waiting at most five days before following up patients [Papers I & II] or considering the in-
fection a secondary bacterial infection [Paper I]. However most uncomplicated viral RTIs last 
between five and seven days and peak in severity between days three and six.
166
 In addition, 
for some self-limiting RTIs like bronchitis and sinusitis, it can take around three weeks 
(sometimes longer) for symptoms to resolve on their own,
161
 therefore providing antibiotics 
this early is likely premature and risks that patients consume antibiotics unnecessarily. 
GPs’ beliefs, coupled with their antibiotic prescribing behaviour, seems to reflect their diag-
nostic uncertainty, with an antibiotic prescription reassuring GPs that should the infection 
aggravate, the patient is already being treated. The lack of current and relevant local antibiotic 
guidelines and data on antibiotic resistance rates in the community augmented their diagnos-
tic uncertainty and was considered a serious barrier to appropriate prescription. In addition, 
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GPs were sceptical of the fact that recommendations are based on foreign evidence, which 
they considered irrelevant. There is therefore a critical need to establish community surveil-
lance systems for antibiotic prescribing and to collect antibiotic resistance data from the 
community. This data must be disseminated to all GPs in a timely fashion to address this im-
minent need. Indeed, surveillance is one of the pillars of antibiotic resistance containment
1,4,21
 
and demands urgent attention in this context. Moreover, in cultures like Malta where diagnos-
tic uncertainty is a dominant cultural trait (according to Hofstede’s model of cultural dimen-
sions Malta’s uncertainty avoidance score is the second highest in Europe44), GPs may bene-
fit from strategies that help alleviate uncertainty such as delayed antibiotic prescribing or de-
cision-support tools like rapid POCTs. Formalising their use in Malta could help reduce un-
necessary antibiotic prescription. 
5.3.1 Delayed antibiotic prescribing 
Delayed antibiotic prescribing is a strategy that has been shown to reduce antibiotic use for 
RTIs by 45-80%, with no major differences in re-consultation rates or significant negative 
repercussions on patients.
167–175
 In spite of its potential, GPs’ perceptions regarding the use of 
this strategy in practice varied greatly [Paper II]. Practical implementation varied too, with a 
patient-led approach being preferred by many GPs. 
Using DAP strategies to address uncertainty was a dominating perception primarily described 
by “Uncertainty Avoiders” but also by “Comforters”. Whilst to “Comforters” DAPs were a 
means of reassuring and comforting patients in uncertain situations, to “Uncertainty Avoid-
ers”, DAP was perceived as a strategy that guarantees that patients have antibiotic treatment 
available to them should their condition worsen. Other studies have also shown that GPs not 
only use DAPs to provide patients or caregivers reassurance and comfort, but also to provide 
reassurance to themselves.
96,176–178
 It can also be considered a safety net or precautionary 
measure in situations that do not warrant immediate antibiotic use. Remarkably, studies from 
the UK and Norway also found that DAPs are provided to manage diagnostic uncertain-
ty,
96,169,176,179
 despite being cultures with comparably lower uncertainty avoidance scores than 
Malta.
30
 The UK however has comparably lower antibiotic consumption and prescription 
rates for colds, flu and sore throat than Malta.
32
 
Apart from DAP potentially being a useful tool to reduce unnecessary prescribing in coun-
tries with high uncertainty avoidance scores, DAPs are provided for other reasons too, as de-
scribed earlier, and these varying perceptions must be considered if standardising the imple-
mentation of DAP in Malta. Studies have shown that doctors prescribe DAPs to safeguard 
patient relationships, although motivations vary.
96,177,180
 For several GPs in Paper II (“Service 
Providers”), DAP was perceived as a means of ensuring a good GP-patient relationship, en-
suring satisfaction and therefore keeping patients in the practice. This was more relevant for 
private sector GPs who expressed concern that dissatisfied patients may visit another GP 
should their expectations not be met. This could affect their income in the long run. Norwe-
gian, UK and New Zealander GPs reported similar concerns, sometimes proving DAPs even 
when not medically indicated
96,97
 to prevent patients from visiting another GP.
177
 There is 
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conflicting evidence as to whether DAP impacts patient satisfaction. Several randomised tri-
als have found no significant difference in patient satisfaction among various prescription 
groups.
167,168,174
 Other studies have shown lower satisfaction rates among patients given a 
DAP than those given immediate antibiotics.
170,171,175
 Conversely, in Norway, 89% of patients 
who received a DAP stated that they would appreciate receiving another in the future.
97
 The 
impact of DAP on patient satisfaction in Malta has yet to be explored. 
“Conscientious Practitioners” considered delayed antibiotic prescribing a means of empower-
ing patients to make their own decisions and educating patients, as has been shown else-
where.
96,97,177,178
 They also recognised that DAPs can help reduce antibiotic use. Both Nor-
wegian and Danish GPs stressed that DAP promotes shared decision-making, providing them 
with an educational opportunity.
97,178
 It was also perceived as a good strategy to reduce anti-
biotic use by both Danish and New Zealander GPs.
177,178
 Notably, UK prescribers expressed 
concern that DAP can potentially deliver contradictory messages to patients regarding when 
antibiotics should be used.
96,179
 Indeed, British patients have reported receiving conflicting 
messages; being issued DAPs after having been informed that their infection was viral.
94
 Ar-
guably, since patients consult early in Malta, combined with the fact that GPs typically pro-
vide DAPs with just a one to three day delay, DAPs might actually provide contradictory 
messages and patients might incorrectly presume that antibiotics are warranted despite most 
likely suffering from a viral infection.
94,96
 However, studies have shown that patients given a 
DAP are less likely to believe that antibiotics are beneficial for their given condition and ex-
hibit lower intent of re-visiting a practitioner for the same infection in the fu-
ture.
167,168,170,172,174
 These important findings stress the importance of providing DAPs under 
the right circumstances and with a clear rationale, explanation and structured advice. 
Finally it is important to consider that some GPs (“Holders of Professional Power”) disagreed 
with DAP because to them, it is the GPs’ responsibility to decide when antibiotics should be 
taken, not the patient’s, which is why they considered DAP unsafe. Similarly, several studies 
found that prescribers deem it safer practice to follow-up the patient in person, and are also 
unwilling to include patients in the treatment decision.
96,178–180
 This approach is congruent 
with cultures that score high in power distance; another Hofstede cultural dimension. In such 
cultures, the GP is considered the expert and may therefore hesitate to relinquish their expert 
power. Additionally, patients in such contexts expect to be told what to do therefore any hesi-
tancy from the side of the expert may be perceived as a lack of confidence.
30
 Consequently, 
by giving a DAP, GPs may be perceived by patients as indecisive, possibly explaining why 
they might avoid this strategy altogether. These prescribers are less likely to adopt DAP strat-
egies, and may require a more targeted approach to address their key concerns. 
5.3.2 Rapid point-of-care tests 
Rapid POCTs may also contribute to reducing antibiotic use in Malta. Rapid POCTs provide 
fast results that can guide clinical management
181
 and have been shown to decrease antibiotic 
use.
182
 If used correctly they have the potential of facilitating diagnostic certainty, therefore 
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eliminating the need for an antibiotic prescription, including a delayed one. To-date, use of 
rapid POCTs in Malta is almost non-existent, primarily due to lack of access to such tests. 
Although point-of-care C-reactive protein testing can lead to reductions in antibiotic prescrip-
tion, as shown in a study carried out in Swedish and Norwegian primary care practices,
183
 it 
does not guarantee appropriate prescription practices. Indeed, in Spain it was shown that de-
spite negative rapid antigen detection tests for acute pharyngitis, antibiotics were still pre-
scribed in more than 30% of cases.
182
 Not surprisingly, this country exhibits rather high un-
certainty avoidance scores. Conversely, another study carried out in Sweden showed that 
rapid POCTs are sometimes used excessively to avoid uncertainty, at the expense of guide-
lines.
184
 Therefore rapid POCTs should be used appropriately and under justified circum-
stances according to established guidelines such as the Centor criteria. 
Rapid POCTs can also provide GPs with better negotiating power particularly with persistent 
patients, as highlighted by GPs in Paper I and previous research.
185
 In a Spanish study, access 
to POCTs was associated with an 18.9% lower antibiotic prescription rate among patients 
who request antibiotics.
186
 Since rapid POCTs can help reduce uncertainty and support GPs’ 
decisions not to prescribe antibiotics, this lessens the risk that they succumb to patient de-
mands.
186,187
 However, GPs expressed that integrating rapid POCTs into practice is impeded 
by time constraints, added costs, lack of resources and possible hesitancy from patients. Con-
sequently, despite generally having a positive outlook towards rapid POCTs, some GPs in-
sisted on relying on their clinical assessment and diagnosis. They believed that rapid POCTs 
would have little impact on their prescribing, as has been reported elsewhere.
185
 Nonetheless, 
the introduction of rapid POCTs for RTIs in Malta should be considered, particularly since 
almost all patients with suspected tonsillitis received an antibiotic prescription. Their imple-
mentation will however need to address barriers to adoption in order to successfully roll-out 
such a strategy on a national level. Their introduction must avoid introducing new elements 
of uncertainty and be combined with training and support to encourage acceptance. Similarly, 
patients should be informed about the possibility of low-cost POCTs to avoid unnecessary 
antibiotic use, thereby safeguarding themselves and their future. Given GPs’ concerns that 
rapid POCTs could burden patients financially, it is important to gain a better understanding 
of patients’ views on rapid POCTs and further identify any other barriers to their uptake. 
5.4 PATIENT DEMAND AND EXPECTATIONS 
Another important aspect of antibiotic prescription is the impact of patient demand and ex-
pectations on GPs. It is reported that GPs experience and are impacted by actual and per-
ceived patient pressure to prescribe antibiotics and that this could lead to unnecessary antibi-
otic prescription, particularly when they do not succeed at persuading patients other-
wise.
35,36,46,163,188–191
 GPs expressed that, although improving, they still experienced patient 
demand for antibiotics [Paper I]. According to some, patients expect antibiotics for a “quick 
fix”, as has been found elsewhere.163 However, our surveillance data revealed that patient 
demand is low and suggests that it may be overestimated by GPs. It is nonetheless important 
to address its impact on antibiotic prescribing as GPs were more likely to prescribe antibiotics 
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to patients who requested them [Paper IV]. In fact, a few GPs admitted to succumbing to the 
pressure of patient demand after failing to convince them otherwise. According to them, 
some patients are impossible to persuade and lack the necessary knowledge to understand 
when antibiotics are necessary. Indeed, lack of knowledge may lead to higher demand for 
antibiotics when they are not needed. Unfortunately, the general public’s knowledge and 
awareness on appropriate antibiotic use remains low and is currently lower than other EU 
countries.
32
 Shifting the public’s mentality and improving knowledge will take time but must 
be drastically improved. 
GPs also reported that patients express dissatisfaction if they do not get their way and some-
times threaten to consult elsewhere which could mean losing a patient to another GP. Similar 
concerns have been reported elsewhere.
36
 One must consider that when patients pay for their 
visit out-of-pocket, GPs may feel more pressure to prescribe antibiotics to avoid losing cli-
ents, avoid reconsultation and/or ensure patient satisfaction.
192
 However, contrary to some 
beliefs, providing an antibiotic prescription does not necessarily guarantee satisfaction. While 
some studies have shown that prescribing an antibiotic to such patients leads to better overall 
patient satisfaction,
189,193
 others have indicated that a proper examination and receiving in-
formation (without antibiotics) leads to higher satisfaction.
194–197
 This would explain why 
communication is sometimes considered more important by patients than a prescription.
198
 
Consequently, whilst it is important to understand why patients expect antibiotics in Malta 
and what determines their satisfaction, GPs need to consider alternative strategies to ensure 
patient satisfaction without providing an unnecessary antibiotic, especially since receiving an 
antibiotic, particularly when expected, reinforces patients’ desire for an antibiotic prescription 
and their belief that they should re-visit a GP for a similar problem.
199
 Whilst national cam-
paigns are important to address the public’s knowledge and misconceptions, GPs are ideal 
educational vessels. They are often the first point of contact, providing a great opportunity to 
inform patients on appropriate antibiotic use. Importantly, GPs took pride in educating pa-
tients. However, certain concepts were considered hard to explain without educational re-
sources. Communication skills training that teaches GPs the necessary skills to address pa-
tient concerns and expectations without compromising the GP-patient relationship, together 
with educational tools that facilitate decision-making and empower doctors to decline antibi-
otic requests, could be effective.
200
 
5.5 INTERACTION WITH DRUG REPS 
It is not uncommon for GPs’ to encounter drug reps who effectively provide one-to-one in-
formation during regular outreach visits.
201–203
 They also use other strategies to promote their 
products, such as information via postal mail, incentives and sponsored educational events.
203
 
GPs mentioned that drug reps use similar tactics in Malta [Paper I] and whilst some appreci-
ated the informative and educational aspect of it, as seen in other studies,
204
 others received 
them with scepticism. Some GPs were particularly hesitant to believe that all the information 
provided to them is true. However, as shown in other studies,
204
 GPs rarely felt that drug reps 
directly impacted their prescribing. Yet exposure to information from pharmaceutical compa-
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nies has been shown to have negative repercussions on the quality and quantity of GPs’ anti-
biotic prescribing.
202,203,205,206
 Indeed, as GPs themselves mentioned, they may be more in-
clined to favour a particular company’s drugs, and prescribe them irrationally.204 So far we 
lack evidence that continued exposure to promotional activities by pharmaceutical companies 
improves antibiotic prescribing, therefore it cannot be recommended.
203
 Restricting the pro-
motion of antibiotics through new legislations should be considered. 
5.6 METHODOLOGICAL CONSIDERATIONS 
In order to achieve a better understanding of GPs’ views on antibiotic prescribing, their anti-
biotic prescription patterns as well as factors that drive their prescribing behaviour, a mixed 
methods approach was employed. Mixed methods research is particularly powerful when 
addressing complex, multifaceted issues, which is often the case in health services interven-
tions.
207
 By using this approach we were able to harness the strengths and offset the weak-
nesses of both quantitative and qualitative methodologies, in order to more comprehensively 
address our research questions. It also gave us the opportunity to triangulate our data (meth-
odological triangulation) to corroborate our findings, thus strengthening their validity.
208,209
 
We specifically used an exploratory sequential approach, meaning that our initial qualitative 
studies were used to inform the subsequent quantitative surveillance study and its analysis, as 
well as the intervention, enabling us to tailor it according to the needs identified in the pre-
ceding phase. Our results helped elucidate the quality and drivers of antibiotic prescribing and 
identify critical areas in need of improvement. Outlined below are some of the methodologi-
cal issues considered in the studies included in this thesis. For ease of understanding, they 
have been broken down into three parts; general considerations for all papers, and specific 
considerations for the qualitative and quantitative research methodologies used. 
5.6.1 General methodological considerations [Papers I-IV] 
5.6.1.1 Self-selection bias 
Despite the fact that GPs exhibited variation across factors of interest, the samples may not be 
representative of all GPs. Since GPs participated voluntarily, it is likely that they were more 
interested in the research topic and may therefore differ from non-participating GPs. Howev-
er, diverse views on and experiences with antibiotic prescription were nonetheless captured. 
Additionally, despite that GPs may have had more interest in the research area, their antibi-
otic prescribing rates still exceeded recommendations which calls into question what the anti-
biotic prescribing patterns for aRTCs are like among non-participants. 
5.6.1.2 Social desirability bias and the Hawthorne effect 
When research subjects are conscious of the fact that they are being observed, they may ad-
just their responses to be viewed more positively by others. It is possible that GPs provided 
more socially-desirable answers or refrained from disclosing sensitive information during the 
interview. In an attempt to avoid this, the interviewer made sure to create a comfortable and 
safe environment for the GPs. The interviewer also asked open-ended questions with appro-
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priate prompts to give GPs the space they need to open up and elaborate about their personal 
experiences and practices. 
During the surveillance study, it is possible that GPs adjusted their diagnoses according to 
their intention to treat with antibiotics. Modifying behaviour when being held under observa-
tion is known as the Hawthorne effect.
210
 Moreover, since audit and feedback is a behaviour 
change intervention in itself and since GPs were issued three-monthly feedback reports, this 
may have influenced their prescribing practices.
133
 However, prescribers were never directly 
observed and the study took place over an extended time which should have allowed pre-
scribers to resume their habitual behaviour. In fact, no evidence was found that GPs’ pre-
scribing patterns changed during the study period as a result of the reports. 
5.6.1.3 Generalisability (external validity) and transferability 
In order to facilitate readers to transfer our findings to other contexts, a thick description of 
the study settings, data collection procedures, participants and data analysis methods used 
was provided. Therefore, although our findings are context-specific, they remain relevant and 
the methods used could be transferred and adapted in other contexts with similar characteris-
tics, particularly Mediterranean countries that share similar sociocultural traits as Malta. 
5.6.2 Qualitative research: specific considerations [Papers I & II] 
To attain a richer and more in-depth understanding of GPs’ views on and experiences with 
antibiotic prescription, and to delve deeper into contextual issues that impact their behaviour, 
a qualitative research approach was considered most effective. It is customary in qualitative 
research to use small, non-probability samples. To achieve variation in background factors, 
we used a stratified non-probability sample technique called quota sampling. This strategy 
accounts for sizes and proportions of sub-samples, with sub-groups ultimately reflecting cor-
responding proportions in the actual population.
211
 It permitted us to better illustrate the varia-
tion in the way antibiotic prescribing was perceived and experienced in our study setting. 
In order to produce good-quality qualitative research, researchers seek to ensure trustworthi-
ness of their findings by following certain criteria, namely: credibility, transferability (dis-
cussed above), dependability, confirmability and reflexivity.
212,213
 Described below are a 
few other measures taken to ensure trustworthiness. 
5.6.2.1 Credibility 
Credibility corresponds to internal validity in quantitative research and different strategies 
can be used to ensure it depending on one’s study design.212 To increase confidence in the 
truth of our research findings, we used investigator triangulation. Whilst two researchers in-
dependently coded and analysed the data, results were later discussed among all co-authors, 
who came from different professional and cultural backgrounds. Incorporating the multiple 
perspectives of various co-authors is important to strengthen one’s findings and ensure cor-
rect interpretation of the interviewees’ views. 
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5.6.2.2 Reflexivity 
The interviewer did not have any previous relationship with any of the interviewees and en-
sured to ask open-ended, objective questions with appropriate prompts so as to avoid direct-
ing GPs’ responses. The research team also strove to bracket any preconceptions that might 
influence the interpretation of results, whilst concurrently allowing their pre-understanding of 
the research topic and context to facilitate deeper understanding of the findings. 
5.6.3 Quantitative research: specific considerations [Papers III & IV] 
Community antibiotic prescribing data from southern European countries is lacking, particu-
larly diagnosis-specific data. Furthermore, knowledge on the drivers of antibiotic prescribing 
in southern European countries with high antibiotic consumption rates is also limited. This 
repeated, cross-sectional surveillance study was the first of its kind in Malta, and provided 
insight into diagnosis-specific treatment and factors that influence it, which is a major 
strength of this study. The study’s design posed two major limitations however. Firstly, since 
the surveillance weeks were static, GPs were occasionally unable to report data during the 
allocated week. Secondly, it was impossible to trace whether patients eventually purchased 
the antibiotic and whether they were compliant to treatment. Described below are measures 
taken to improve the study’s validity and reliability, and assure data quality. 
5.6.3.1 Validity, reliability and measurement error 
To ensure the validity (i.e. accurate measurement of the problem)
214
 of the research instru-
ment, the data collection tool was developed based on previous research and prior knowledge 
of the study setting. This was done in collaboration with experienced researchers involved in 
the project. The tool was subsequently pilot tested for face validity and adapted accordingly. 
Measures were also taken to ensure the reliability (i.e. consistent measurement) of the data 
collection tool.
214
 To reduce measurement errors (systematic bias and random error), partici-
pating GPs were given detailed instruction sheets on how to use the data collection instru-
ments. This was explained verbally to the GPs by the same researcher during a one-to-one 
meeting. GPs were also encouraged to raise questions and concerns with the data collection 
tool during the entire surveillance period. Furthermore, since data were first entered by the 
author of this thesis, and later taken over by a research assistant under supervision, measures 
were taken to ensure the continued quality and consistency of data input. Random data 
checks were also made by the supervisor (the author of this thesis). 
Despite measures taken to reduce measurement errors, it is possible that GPs recorded patient 
information without directly asking patients, possibly providing inaccurate demographic in-
formation. It is also possible that variables of interest inserted at the end of the surveillance 
sheet were left unmarked, perhaps due to time constraints, and inaccurately assumed to be 
non-cases. However, the audit sheets were specifically designed to be time-efficient. In fact, 
many GPs were easily able to integrate them into their practice. 
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6 CONCLUSIONS 
Through our studies and this thesis, it has been shown that GPs’ prescribing decisions are 
seldom influenced by clinical factors alone. Indeed, antibiotic prescribing is also influenced 
by a range of social and cultural factors,
96,176,197,215,216
 at several levels of influence.
217
 Con-
text plays a dominant role in determining appropriate antibiotic use, and improving prescrib-
ing behaviour requires a concerted effort that addresses a variety of medical, social and cul-
tural influences, as well as broader system factors (including organisational factors), in order 
to be accepted and effective.
217,218
 
This critically needed insight was acquired through our studies, by gaining a better under-
standing of GPs’ views on antibiotic prescription for RTIs and perceived barriers and facilita-
tors to change. Through the socioecological model, the complexity of antibiotic prescribing 
and the numerous influences on GPs’ antibiotic prescribing behaviour were also illustrated. 
Furthermore, data on GPs antibiotic prescribing patterns for aRTCs and key drivers of anti-
biotic prescription were also attained. It is evident that improving their antibiotic prescribing 
will require change at not just the individual level, but across all levels. These findings can 
not only help guide antimicrobial stewardship initiatives in Malta, but also those in countries 
with similar sociocultural traits. 
Outlined below, are the key conclusions of this thesis: 
 GPs’ antibiotic prescribing for aRTCs in Malta is high, indicating that antibiotics are not 
being used appropriately.  
 The abundant prescription of broad-spectrum antibiotics, particulary that for the empiric 
treatment of aRTCs that are unlikely to require antibiotic treatment, is concerning. 
 GPs raised concerns that they are forced to prescribe blindly since they lack access to up-
to-date and relevant local antibiotic prescribing guidelines as well as antibiotic resistance 
data from the community. Therefore large caveats remain in Maltese primary care, 
leading to further uncertainty in the treatment of aRTCs, and most likely unnecessary 
and inappropriate antibiotic prescription. 
 Rapid POCTs remain largely unavailable and are thus rarely used in Maltese primary 
care, with many GPs stating that even if they were to be introduced, barriers such as the 
lack of human resources, time and cost will hinder their uptake and use. 
 GPs hold widely varying perceptions on delayed antibiotic prescribing with some GPs 
being largely in favour of the strategy and others preferring a wait and see approach 
without providing a DAP. There is also some variation in the way DAP is currently 
being employed in Malta. 
 Although GPs do not always believe the information provided to them by drug reps, 
several appreciated receiving up-to-date information, particlarly since they have 
difficulty keeping themselves updated with the latest medical advancements and 
products. 
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To conclude, antibiotic resistance is a public health threat that respects no borders.
11
 Despite 
its political prioritisation and the availability of evidence to help inform antimicrobial stew-
ardship activities, public health action remains inadequate.
38
 Given the magnitude of this 
global, multi-sectoral problem, it is critical for researchers, industries (pharmaceutical, agri-
cultural, food), policy-makers, politicians and other major stakeholders to coalesce and ad-
dress this escalating situation promptly. Tackling antibiotic misuse in primary care addresses 
only one small piece of the puzzle but is necessary since vast amounts of antibiotics are con-
sumed in the community setting. Curbing antibiotic misuse in the community will entail the 
implementation of tailored multifaceted interventions that target not only medical practition-
ers but also patients and pharmacists. If we are to continue to successfully treat patients in 
need of antibiotic therapy in the future, simple but effective solutions that take local culture 
into consideration and that can be scaled up to become self-sustainable, must be implemented 
promptly in order to safeguard the ‘miracle’ drugs of the 20th century. 
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7 RECOMMENDATIONS FOR RESEARCH AND POLICY 
Outlined below are recommendations for future research and policy, based on our findings. 
7.1 ANTIBIOTIC PRESCRIBING SURVEILLANCE 
For any antibiotic stewardship activities to succeed, continued prescribing surveillance in the 
outpatient setting is critical. To-date no coordinated electronic system exists in Maltese pri-
mary care to collect electronic prescribing data but also to provide prescribers with access to 
electronic prescribing guidelines. This also means that there is little accountability for antibi-
otic prescribing. Furthermore, without such a necessary resource, it is near impossible to un-
derstand antibiotic prescription patterns in the community, monitor trends and evaluate inter-
ventions.
62
 Audit and feedback with peer comparison specifically, has the potential of im-
proving GPs’ prescribing habits and is recommended. Furthermore, research on prescriber 
concordance to guidelines is necessary and will not be possible without much needed surveil-
lance data. To this end, a more comprehensive antibiotic prescribing surveillance system is 
critically needed in Malta. 
7.2 NATIONAL ANTIBIOTIC GUIDELINES 
So far, it appears that national antibiotic guidelines have not been widely accessible, partly 
due to GPs’ lack of awareness of their availability. This suggests that updated national guide-
lines must be better disseminated among GPs in both the private and public sectors and their 
availability be more widely known. Making guidelines available on mobile applications could 
make them easier to carry around and potentially increase their usability, however this re-
quires further investigation. Furthermore, guidelines should include other diagnostic criteria 
that pose dilemmas to GPs, such as what to prescribe to patients with specific antibiotic sensi-
tivities, preferences, co-morbidities or to smokers. When it comes to DAP recommendations, 
guidelines should better promote DAP through diagnosis-specific suggestions that take the 
natural progression of illness into account. 
7.3 DELAYED ANTIBIOTIC PRESCRIBING 
Given the potential that DAP has to reduce antibiotic use for RTIs, formal and standardised 
implementation of DAP could aid curb antibiotic overuse and help the general public under-
stand that antibiotics are not always necessary for RTIs. Prescription pads specifically de-
signed for post-dated antibiotics could help serve this purpose. However, this must be cou-
pled with structured patient advice and widespread dissemination of information about the 
purpose and benefits of this strategy among not just doctors, but patients and pharmacists too. 
Furthermore, since DAP has a potential influence on patient satisfaction, further investigation 
on patients’ views on delayed antibiotic prescribing and how their expectations can be met is 
recommended. 
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7.4 RAPID POINT-OF-CARE TESTING 
Introducing rapid POCTs could positively impact antibiotic prescribing if utilised correctly. 
With the right implementation strategy that ensures that barriers such as cost and time are 
addressed, the introduction of low-cost, rapid POCTs could prove valuable to support GPs’ 
prescribing decisions in this context, more so since diagnostic uncertainty was considered a 
problem. 
7.5 CONTINUING MEDICAL EDUCATION 
Educating prescribers is important to overcome antibiotic misuse.
104
 Currently however, con-
tinuing medical education, even on antibiotics, are often sponsored by the pharmaceutical 
industry in Malta; a serious conflict of interest.
62
 Therefore unbiased, regular educational 
activities are needed to promote appropriate and evidence-informed antibiotic prescription 
practices. Although GPs with many years of experience could benefit more from continuing 
medical education, all GPs should be given the opportunity to participate in educational activ-
ities that help raise GPs’ awareness on appropriate prescribing by indication and patient 
group. Educational activities should specifically target the over-prescription of broad-
spectrum antibiotics and provide GPs with the latest antibiotic prescribing recommendations 
according to national antibiotic guidelines. GPs could also benefit from communication train-
ing to facilitate decision-making and empower doctors to decline antibiotic requests. This can 
be combined with the introduction of educational tools for patients that can be used during 
consultations and help support GPs in patient education. Developing targeted sessions, tai-
lored toward the specific needs of a particular GP demographic, may prove even more bene-
ficial. 
7.6 ACADEMIC DETAILING 
Several GPs appreciated the interaction they had with drug reps and found them informative, 
particularly those working in solo practices that got little opportunity to interact with other 
healthcare professionals. However, such information is likely to be biased as drug reps are 
motivated to boost sales. Similar to strategies used in drug repping, in academic detailing, 
doctors receive one-to-one educational visits by a trained healthcare professional in their own 
professional setting.
219
 This method, is successful at reducing antibiotic prescription rates 
whilst improving guideline-concordance.
220,221
 It provides GPs with an opportunity to reflect 
upon their own prescription practices and get informed about the latest recommendations for 
appropriate antibiotic treatment.
188
 With enough resources, this strategy has great potential in 
this setting. It can be used as a means of disseminating up-to-date local antibiotic prescribing 
guidelines as well as data on antibiotic resistance rates in the community. It could also pro-
vide a platform for GPs to discuss specific guideline recommendations with a trained profes-
sional, particularly for those diagnoses where the benefits of an antibiotic prescription are 
limited (e.g. uncomplicated acute bronchitis and rhinosinusitis). This form of outreach is 
therefore likely to have great impact in this setting which is why academic detailing by relia-
ble, unbiased, medical professionals is highly recommended and should be piloted to assess 
its effectiveness. 
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7.7 REVISION OF SICK LEAVE POLICIES 
Currently, sick leave certification provided by a medical doctor is required from the first day 
of illness if one intends to claim social security benefits after the third day of illness.
222
 This 
encourages early consultations, particularly with GPs, since they are usually the patient’s first 
point of contact for an acute illness. Revision of this sick leave policy could help reduce un-
necessary and early antibiotic prescription. 
7.8 GENERAL PUBLIC KNOWLEDGE, AWARENESS AND BEHAVIOUR 
More research is needed to not only better understand patients’ views on antibiotics and their 
appropriate use, but also how they perceive various strategies to limit antibiotic use and use 
them more appropriately. Further investigating their attitudes towards delayed antibiotic pre-
scribing and rapid POCTs in particular, could help support our findings and better inform 
their successful implementation and integration into clinical practice in Malta. 
Additionally, since the general public’s knowledge and awareness on correct antibiotic use 
remains sub-optimal, it must be improved. People need to understand the difference between 
viral and bacterial infections, the natural course of various infections and that viral infections 
do not require antibiotic treatment. They must also be encouraged to engage in self-care for 
simple ailments such as the common cold before visiting a doctor, in order to discourage ear-
ly consultation. Nationwide campaigns that harness the power of social media could prove 
effective, with appropriate key messages delivered in an easy and comprehensible manner. 
7.9 PHARMACIST INVOLVEMENT 
To-date little is known about pharmacists’ views on their role in halting the development of 
antibiotic resistance in Malta which calls for further research in this area. Pharmacists are a 
key stakeholder, not only as dispensers of antibiotics but also educational vessels to patients 
and close collaborators with GPs. Their involvement in this dynamic cannot be overlooked. 
 
 
 
 
“There is no single solution and several, synergistic, overlapping, and com-
plementing approaches will be needed, with a strong overarching shared goal 
to ensure and sustain access to effective antimicrobial therapies.” 
– Holmes et al. (2016)7 
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AbstrAct
Introduction Antibiotic misuse is a key driver of 
antibiotic resistance. In 2015/2016, Maltese respondents 
reported the highest proportions of antibiotic consumption 
in Europe. Since antibiotics are prescription-only 
medicines in Malta, research on effective strategies 
targeting general practitioners’ (GPs) knowledge and 
behaviour is needed. Multifaceted behaviour change (BC) 
interventions are likely to be effective. Social marketing 
(SM) can provide the tools to promote sustained 
BC; however, its utilisation in Europe is limited. This 
paper aims to describe the design and methods of a 
multifaceted SM intervention aimed at changing Maltese 
GPs’ antibiotic prescribing behaviour for patients with 
acute respiratory tract infections (aRTIs).
Methods and analysis This 4-year quasiexperimental 
intervention study will be carried out in Malta and 
includes three phases: preintervention, intervention and 
postintervention. The preintervention phase intends to gain 
insight into the practices and attitudes of GPs, pharmacists 
and parents through interviews, focus group discussions 
and antibiotic prescribing surveillance. A 6-month 
intervention targeting GPs will be implemented following 
assessment of their prescribing intention and readiness 
for BC. The intervention will likely comprise: prescribing 
guidelines, patient educational materials, delayed 
antibiotic prescriptions and GP education. Outcomes 
will be evaluated in the postintervention phase through 
questionnaires based on the theory of planned behaviour 
and stages-of-change theory, as well as postintervention 
surveillance. The primary outcome will be the antibiotic 
prescribing rate for all patients with aRTIs. Secondary 
outcomes will include the proportion of diagnosis-specific 
antibiotic prescription and symptomatic relief medication 
prescribed, and the change in GPs stage-of-change and 
their intention to prescribe antibiotics.
Ethics and dissemination The project received ethical 
approval from the University of Malta’s Research Ethics 
Committee. Should this intervention successfully decrease 
antibiotic prescribing, it may be scaled up locally and 
transferred to similar settings.
trial registration number NCT03218930; Pre-results.
bAckground
Access to effective antibiotic treatment is a 
prerequisite in healthcare today.1 Unfortu-
nately, however, widespread antibiotic use 
has accelerated the rate of antibiotic resis-
tance (ABR) development.2 Although the 
exact magnitude of this global problem 
and its impact on human health is largely 
unknown,2 ABR in common bacterial patho-
gens has reached concerning levels in many 
parts of the world.2 As a result, many available 
treatment options are becoming ineffective,2 
forcing us to resort to more potent, toxic and 
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strengths and limitations of this study
 ► This study is the first in Malta that attempts to 
establish an ongoing community surveillance system 
to gather timely data on diagnosis-specific antibiotic 
prescribing among general practitioners  (GPs) in 
Malta.
 ► This study is also the first to employ social marketing 
techniques to design, deliver and evaluate the 
effectiveness of a behaviour change intervention to 
improve antibiotic prescribing in Malta.
 ► If effective, this intervention could easily be 
incorporated into routine clinical practice and scaled 
up locally and extrapolated to similar settings, 
particularly in the Mediterranean region, at a very 
low cost.
 ► In the long  term, this intervention could help 
contribute towards reducing the development of 
antibiotic resistance, which is an ever-growing 
challenge.
 ► Given the country’s size and number of active GPs, 
a randomised controlled trial will not be possible; 
therefore, the intervention’s effect may be harder 
to assess; it may have a smaller effect than 
expected. In order to allow for better detection of the 
intervention’s effectiveness on behaviour change, a 
quasiexperimental design shall be employed.
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costly drugs, often with considerable side effects.3 Anti-
biotic-resistant infections pose substantial burden on 
patient outcomes and health expenditure, both at soci-
etal and individual levels.2 4 They lead to significantly 
longer hospital stays, increased morbidity and mortality3 
among others.
ABR is complex and driven by many interrelated 
factors, including knowledge, attitudes, perceptions, 
expectations, time constraints, economic incentives, 
cultural factors, health system characteristics and regu-
lations.5–9 A recognised key driver is the use, misuse or 
overuse of antibiotics, as well as unregulated consumer 
access to antibiotics.6 10 11 While antibiotic overuse plays 
a pivotal role, underuse through inadequate dosing and 
poor adherence also plays an important role.6
Although a correlation between outpatient antibiotic 
consumption and ABR has been shown in Europe, the 
association is complex.12 13 While the highest concentra-
tions of antibiotic prescribing is in inpatient settings,14 
the overall quantity of antibiotic prescribing is highest 
in the community.15 Indeed, the highest rates of antibi-
otic prescription for systemic use are in primary care,16 
with respiratory tract infections (RTIs) being the most 
common diagnoses.17 Studies have shown alarmingly 
high rates (between 50% up to almost 100%) of antibi-
otics prescribed for upper RTIs in outpatient settings, 
even though seldom required.18–23
In Malta, a southern European country, wholesale 
distribution records have shown that antibiotic consump-
tion in primary care has increased steadily over the past 
decade, despite a reduction in over-the-counter sales.24 In 
fact, in a 2016 European-wide study, 48% of the popula-
tion reported taking antibiotics during the previous year; 
the highest in the European Union.25 The top two indi-
cations were sore throat (22%; EU28 average 14%) and 
influenza (18%; EU28 average 16%).25 This was accom-
panied by suboptimal levels of knowledge on antibiotics 
among the general population; only 27% of the Maltese 
interviewed knew that antibiotics do not kill viruses, and 
only 39% knew that antibiotics are ineffective against 
cold and influenza.25 Although knowledge has increased 
slightly since the two preceding surveys,26 27 awareness is 
still low compared with other European countries.
Through the European Antibiotic Awareness Day,28 
attempts to increase knowledge and awareness among 
the Maltese public, prescribers and pharmacists have 
been made and regulations enforced. Consequently, 
self-medication has fallen from 19% of Maltese respon-
dents admitting taking antibiotics without a prescription 
in 2001 to 2% in 2016.24 25 As doctors are considered the 
most trustworthy source of information on antibiotics by 
the Maltese,25 they are important role models for their 
patients. The future challenge is to promote better anti-
biotic prescribing behaviour among general practitioners 
(GPs),17 24 29 particularly since 97% of antibiotic consump-
tion in Malta results from a medical prescription.25
Research on effective strategies targeting prescriber 
knowledge and behaviour are needed to promote 
appropriate antibiotic prescribing and consumption.9 12 30 
The local cultural context plays an important role and 
cannot be overlooked.31 Hofstede’s model of cultural 
dimensions describes how cultures vary along groups 
of fundamental dimensions, namely power distance, 
individualism, masculinity and uncertainty avoid-
ance. Scandinavian countries show very low scores for 
power distance, masculinity and uncertainty avoidance; 
conversely, Mediterranean countries are characterised 
by high power distance and uncertainty avoidance, and 
medium to high masculinity scores.32 Consequently, a 
positive association between power distance and outpa-
tient antibiotic consumption, including self-medication, 
has been shown.33 In countries with high uncertainty 
avoidance, antibiotic prescribing can provide the clini-
cian with a subconscious reassurance of certainty. In 
such contexts, antibiotic prescribing would presumably 
be high and more likely prescribed ‘just in case’ when 
faced with dubious clinical presentations.34 Since change 
generates uncertainty, such cultures tend to be more 
resistant to change making behaviour change initiatives 
more challenging, particularly since national culture and 
unspoken rules are key drivers behind inappropriate anti-
biotic prescribing behaviour.34–36 Successful interventions 
must recognise local key drivers of prescribing and incor-
porate incentives to alter behaviour into stewardship 
programmes.35
While awareness campaigns and education are often 
recommended,6 9 13 interventions targeted specifically 
at changing behaviour are more likely to be effective. 
Behavioural theories, such as the theory of planned 
behaviour37 and the stages-of-change model,38 and 
social science methods have been suggested as suitable 
approaches to better understand factors influencing 
prescribing practices.39 These methods have thus far 
been underutilised in the development of interventions 
targeting antibiotic prescribing.39 Other European coun-
tries have attempted to use a behaviour change approach 
to promote prudent antibiotic use, although most did not 
consider the behavioural determinants related to antibi-
otic use and prescribing.39 Moreover, interventions that 
attempt to reduce inappropriate antibiotic prescribing 
tend to be more successful when they combine physi-
cian, patient and public education and when the design 
is multifaceted.17 40–43 Social marketing (SM) may provide 
a different insight on the development of health promo-
tion initiatives targeting the prevention of ABR.
SM is a behavioural science approach to promote social 
change by applying marketing theories and techniques 
to plan, implement and evaluate interventions to induce 
voluntary behaviour change.44 It combines concepts from 
commercial marketing and health communication into 
the following principles: behavioural focus, ‘customer’ 
orientation, segmentation (ie, tailoring), competition 
(ie, understanding benefits and barriers), exchange (ie, 
emphasis on the benefits of changing one’s behaviour), 
marketing mix (the ‘4Ps’ of marketing: product, price, 
place and promotion) and long-term planning. It also 
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considers context-specific issues to tailor interven-
tions conducive to the country’s particular needs, thus 
increasing one’s chances of success.44 When applied 
correctly, SM interventions can provide the necessary 
tools to promote sustained behaviour change among 
targeted populations.30 The utilisation of SM for the 
prevention and control of communicable diseases in 
Europe has however been limited.44 This paper aims to 
describe the design and methods of a multifaceted SM 
intervention aimed at changing Maltese GPs’ antibiotic 
prescribing behaviour for patients with acute RTIs.
MEthods
study design
A 4-year quasiexperimental intervention study protocol, 
based on SM principles, was designed to assess whether 
a multifaceted SM intervention is effective at influencing 
GPs’ antibiotic prescribing practices for acute RTIs. The 
SM intervention was developed in a multistage process, 
following a BEHAVE-based marketing plan45 (figure 1). 
The BEHAVE framework allows you to address simple but 
essential questions prior to deciding what interventions 
to implement, namely (1) who is the audience?, (2) what 
do you want them to do? and (3) what factors influence 
their behaviour?45 The study will be described stage-wise 
according to the three different phases: preintervention, 
intervention and postintervention.
study setting
The intervention will be rolled-out in Malta, a southern 
European country (316 km2; 425 384 population; 2013 
est.) and one of the smallest yet most densely popu-
lated countries in the world (1346 persons/km2).46 The 
nation has two official languages: Maltese and English. 
Malta has an integrated health services system organised 
at national level, primarily funded by taxation (65%) 
and complemented by private financing (out-of-pocket 
and insurance).47 Hospital-based healthcare is predomi-
nantly public (96%) and free at point-of-care to all citi-
zens, whereas approximately two-thirds of primary care 
is provided by the private sector47 and mainly delivered 
by GPs. As from 2003, qualified doctors are expected to 
specialise as GPs; however, GPs practising prior to 2003 
were granted certified specialisation through a grand-
father clause, based on acquired experience.48 All GPs 
are registered on the Malta Medical Council’s Medical 
and Dental Specialists Register. Publicly financed health 
services in primary care are also free at point-of-delivery. 
Around 80% of antibiotic use in ambulatory care takes 
place through prescription following a paid consulta-
tion by a private GP. No reimbursement system exists, 
although a small proportion of the population are eligible 
to receive—free of charge—a restricted list of antibiotics 
directly from government pharmacies.
Primary care is available all day, all year round; GPs are 
essentially on-call 24/7, especially since most private GPs 
have strong family ties with their patients and often treat 
several generations within the same family. Most GP clinics 
in the public sector are walk-in clinics, and patients are 
not registered with any particular doctor or group prac-
tice, thereby impeding continuity of care. In the private 
sector, GPs work mostly in single-handed practices (group 
practices remain uncommon), and patients are free to 
choose their own GP. They often practice within retail 
pharmacies or private clinics,47 although home visits are 
high on demand and relatively common. In this highly 
regulated system, antibiotics are prescription-only medi-
cines, acquired from community pharmacies through a 
non-refundable personal purchase.24 49 As of yet, phar-
macies do not keep electronic records of prescriptions 
dispensed; therefore, prescription-level data are currently 
unavailable.24 Likewise, GPs are not obliged to keep 
patient records, although some do so for personal use.
Formative research: the preintervention phase
One of the pediments of any successful SM intervention 
is an in-depth understanding of the target audience.50 
Without thoroughly understanding how the target 
audience view antibiotic use and resistance within their 
own context, there would be little chance for success in 
achieving behaviour change.50 Formative research is the 
best way to gain insight into the practices and attitudes 
of potential audience members and can be achieved 
through focus group discussions (FGDs) and individual 
interviews, among others.
The preintervention phase consists of three substudies 
that will inform subsequent substudies and the develop-
ment of the intervention strategy. During this phase, base-
line data will be collected using mixed methods.
Individual face-to-face interviews with GPs (substudy I)
In order to design a tailored intervention, understanding 
key issues, particularly contextual factors, which influ-
ence GPs’ antibiotic prescribing practices, is essential. 
Therefore, this substudy seeks to explore GPs’ views 
and understanding of prudent antibiotic prescribing as 
well as factors that influence their antibiotic prescribing 
practices. It further aims to understand the variation 
in GPs’ perceptions on delayed antibiotic prescribing 
(defined later). For this qualitative exploratory study, 
individual semistructured interviews will be held with a 
quota sample of 15–20 active GPs registered at the Malta 
Medical Council. In quota sampling, the intention is to 
ensure that the strata within the sample under study are 
proportional to those in the population being studied.51 
GPs are eligible to participate regardless of whether they 
work on a part-time or full-time basis or in the public 
and/or private sectors, the latter distinction considered 
advantageous. All eligible GPs registered at the Malta 
Medical Council, and to whom a phone number is avail-
able, will be included as possible interviewees. Once the 
list is finalised, GPs will be divided into strata based on the 
following characteristics and in the following order: (1) 
years of experience, (2) sex and (3) locality of residence. 
GPs from within each stratum will be contacted by phone 
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Figure 1 A BEHAVE-based marketing plan for a social marketing intervention.
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in a stepwise fashion until 15–20 GPs are recruited, alter-
natively until data saturation is reached. These measures 
will ensure that the sample of interviewees is as represen-
tative of the population characteristics as possible.
A semistructured interview guide (with prompts) will 
be designed and developed based on a thorough litera-
ture search and adapted according to the local context. 
The guide will be pilot-tested with a purposive sample of 
up to five GPs, following which it will adjusted accord-
ingly. Interviews will be held in English and/or Maltese 
by one member of the research team who is fluent in both 
languages and are expected to last around 45 minutes. 
The recorded interviews will be transcribed verbatim 
and translated if necessary. Data will be analysed using 
content analysis and phenomenography. An overview of 
the design of this substudy and subsequent ones can be 
found in table 1.
Findings will be used to identify competing behaviours 
as well as barriers and facilitators to behaviour change. 
By understanding what GPs want, they can be offered 
optimal conditions for exchange, that is, offering them 
something they consider worthwhile in exchange for 
them changing their behaviour. This is based on the 
premise that if people believe that something is of benefit 
to them, they will act on it; barriers stop them from acting. 
Therefore. the intervention should ensure that activities 
will maximise the benefits while reducing the barriers 
that are considered important to the target audience.52
FGDs with GPs, pharmacists and parents (substudy II)
Correct antibiotic use depends on various key stake-
holders, including pharmacists, the general public and 
GPs, among others. In order to gain a better under-
standing of the antibiotic prescription–use–dispensation 
dynamic in Malta through these three different stake-
holders, FGDs will be held. Since young children are 
likely to visit their GP often, parents of children under 
the age of 12 will be targeted. Two to three FGDs will 
be conducted for each individual stakeholder—parents, 
GPs and community pharmacists (six to nine groups in 
total)—each consisting of between 6 and 10 participants. 
The target groups will be recruited differently. GPs partic-
ipating in interviews will be reinvited to participate in 
the group discussions. For community pharmacists and 
parents, snowball sampling51 will be employed. Snowball 
sampling will be used in order to gain access to partici-
pants interested in discussing the topic, thus reducing the 
risk for non-participative interviewees. Other sampling 
methods would be too time-consuming to employ and 
may risk inviting persons who will not contribute to the 
discussion.
Community pharmacists will be invited to partici-
pate through local professional associations and social 
networks. Those interested will be asked to recommend 
up to three other pharmacists they believe would be inter-
ested in participating in this study. Parents will be invited 
through schools via school administration and staff 
members with whom the researchers already have contact 
with. Parents interested in participating will be asked to 
recommend up to three parents. Although this type of 
sampling method will allow us to gain timely access to 
both stakeholders, it is limited in the fact that there is 
a high possibility that those interested recommend their 
close peers thus restricting the inferences that can be 
made about the rest of the population. This however is 
not the main goal of this substudy.
Both GPs and community pharmacists must be actively 
working at their time of participation, while parents must 
be the caregiver of at least one child under 12 years of 
age. A discussion guide (with prompts) will be devel-
oped, and FGDs will be held in English and/or Maltese 
by one member of the research team who is fluent in both 
languages, together with an observer/note-taker. FGDs 
are expected to last no longer than 2 hours. The recorded 
FGDs will be transcribed verbatim and translated if neces-
sary. Data will be analysed using content analysis.
Setting up a surveillance system using a repeated cross-sectional 
design (substudy III)
Effective surveillance is the foundation for national and 
international efforts to contain ABR.6 One of the strategic 
objectives of the 2015 global action plan on antimicrobial 
resistance is to strengthen knowledge through surveil-
lance and research.53 There are currently large knowl-
edge gaps on antibiotic use in many regions of the world 
due to the lack of adequate surveillance systems.6 The 
lack of data is often greater in the community setting.2 
Such data would help assess and monitor the situation, 
better understand ABR trends, define optimal treatment 
for patients, identify key areas for interventions to contain 
resistance and monitor their impact and inform public 
health policy.2 6
In Malta, ABR and consumption data are routinely 
collected within tertiary care, and wholesale data are 
collected within the community setting; however, commu-
nity antibiotic consumption data at prescription-level are 
still unavailable,24 and as mentioned earlier, GPs are not 
obliged to keep patient records. Without ongoing surveil-
lance, it is challenging, if not impossible, to devise strate-
gies tailored towards specific needs for the local context. 
Furthermore, it would be difficult to measure whether any 
intervention in such a community would have an impact 
on antibiotic prescribing. In order to better understand 
the antibiotic prescribing patterns of GPs for respiratory 
tract complaints in Malta, we will set up a basic surveil-
lance system to present the baseline 1 year diagnosis-spe-
cific antibiotic prescribing patterns for respiratory tract 
complaints.
All GPs registered on the Malta Medical Council’s 
Specialists Register will be invited to participate. The invi-
tation will also extend to GP trainees. In order to fulfil 
eligibility criteria, GPs must be actively practising at the 
time of recruitment, with no distinction made between 
those working on a part-time or full-time basis. In order to 
attract as many GPs as possible, postal invitations will be 
sent to all GPs registered at the Malta Medical Council and 
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to whom postal addresses are publicly available. This will 
be followed by one postal reminder. Other recruitment 
strategies will also be explored, including sending out 
email invitations through local professional organisations 
and colleges and publishing a public announcement on a 
local medical professionals’ network (TheSynapse; www. 
thesynapse. eu), in an attempt to reach out to those GPs 
without an available postal address. Phone calls will also 
be made to recruit as many interested GPs as possible. GP 
trainees will be recruited via email invitation through the 
Malta College of Family Doctors, who are responsible for 
ensuring the quality of academic training in the GP foun-
dation programme.
Participating GPs will be required to manually collect 
surveillance data for all patients seen with a respiratory 
tract compliant, over a predetermined 1-week period 
(with no substitutions), every month, for a total duration 
of 1 year, resulting in a total of 12 surveillance weeks. A 
surveillance form will be developed for this purpose 
following a thorough literature search. It will also be 
based on data collected in the previous substudies as well 
as previous work carried out in other European coun-
tries.54 55 It will include data on: (1) patient characteris-
tics such as age, comorbidities and lifestyle factors, (2) 
clinical characteristics such as duration of symptoms, 
signs and symptoms, (3) diagnostics and (4) prescription. 
The form will be adapted to the local context through 
piloting and face validity testing. GPs will also be required 
to provide the total number of patients seen during the 
surveillance week, irrespective of their compliant, using a 
designated tally chart.
In order to promote compliance, GPs will receive three 
text messages in conjunction with each surveillance 
week: one a day prior to the initiation of the surveillance 
week,  another on the day and the third at the end of 
the surveillance week. Once the surveillance week is over, 
they will be requested to submit all forms filled together 
with a tally chart by postal mail using prepaid postal 
envelopes. Phone contact will be regularly maintained 
to provide encouragement and resolve queries. While no 
direct incentives will be provided to promote GP partici-
pation, GPs will be provided with certificates of participa-
tion at the end of each intervention phase that will allow 
them to redeem continuing medical education credits 
through the Malta College of Family Doctors. GPs will also 
receive 3 monthly feedback reports summarising the data 
collected during the preceding three surveillance weeks 
(individual and aggregated). Although a form of audit 
and feedback, the primary intention is not to change 
prescribing behaviour at this point rather to encourage 
GPs to continue participation by maintaining regular 
contact. For this reason, we opted not to actively carry out 
any peer comparison, although GPs could compare their 
personal report with the aggregate results.
Descriptive statistics will be used to describe all variables 
collected through the surveillance. The 1 year antibiotic 
prescribing patterns as well as diagnosis-specific antibi-
otic prescribing rates and characteristics will be reported. 
Should the data permit, it will be further analysed to look 
into factors that influence GPs’ antibiotic prescribing 
using mixed effects logistic regression models to take into 
account clustering at GP level.
Intervention development, design and implementation: the 
intervention phase
Following the completion of substudy III, members of the 
research team will carry out outreach visits to all partici-
pating GPs, who will be invited to extend their participa-
tion to the intervention and postintervention phases of 
the project (described below). The intervention phase is 
expected to last 6 months.
Behavioural intention to prescribe antibiotics and readiness for 
change (substudy IV)
Changing prescribing behaviour is complex; however, 
behavioural theories can help better understand and 
influence it through stronger and enhanced development 
and delivery of tailored interventions.52 In order to further 
tailor the intervention according to participating GPs’ 
needs, this cross-sectional survey aims to determine GPs’ 
behavioural intention (attitudes, subjective norms and 
perceived behavioural control) to prescribe antibiotics 
and their readiness for behaviour change. Two question-
naires will be developed for this purpose using the main 
constructs of selected behaviour change theories, namely 
(1) the theory of planned behaviour, which is a conceptual 
framework for understanding social behaviour, focusing 
on the intention to perform a specific behaviour37 and (2) 
the stages-of-change model, which describes the behaviour 
change process: precontemplation, contemplation, prepa-
ration, action, maintenance and relapse.38 Potential topics 
will include: current antibiotic prescribing practices, 
knowledge-based questions on antibiotics (focusing on 
RTIs), likely repercussions of antibiotic misuse, external 
influences to antibiotic prescribing and guideline adher-
ence. Questionnaires will be delivered to GPs prior to 
the initiation of the intervention (baseline) and once the 
intervention is complete (substudy VI). Data will be anal-
ysed using appropriate statistical methods.
Design and implementation of a tailored, multifaceted SM 
intervention (substudy V)
All intervention materials will be designed following 
thorough formative research and consideration of local 
cultural factors and needs. The intervention will also be 
tailored according to GPs’ stage of behaviour change. 
Furthermore, ratification of all intervention materials by 
the local National Antibiotic Committee will be sought 
prior to their dissemination. A number of strategies 
within primary care have been outlined in an effort to 
combat the development of ABR.31 Based on findings 
from the previous substudies, multiple components will 
be developed for this intervention, each described below.
Dissemination of antibiotic prescribing guidelines
Prescribing guidelines aid clinicians in translating 
best evidence to practice. Although several countries 
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have issued national antibiotic guidelines, there is little 
recent evidence that assesses its impact on prescribing 
behaviour.31 It has been shown however that guideline 
dissemination alone is not sufficient to restrict antibiotic 
prescribing.17 For this reason, hard and soft copies of 
the updated national guidelines shall be disseminated to 
every participating GP in combination with other strat-
egies outlined below. Guidelines will be published in 
English.
Distribution of educational materials (including posters and 
booklets)
Over the past decade, the popularity of patient informa-
tion leaflets in primary care has increased.31 They can be 
referred to by doctors during consultations, and patients 
may also take them to home read later.31 A number of 
studies have shown that the use of patient informa-
tion booklets can help to reduce antibiotic prescribing 
rates56 and provide patients with valuable information 
on the typical duration of illness, how to recognise signs 
of severe illness and increase awareness on antibiotic 
use.57 58 They also lead to increased knowledge and 
confidence among GPs, although some report certain 
barriers such as lack of time and problems changing 
their consultation style.57
Should posters be developed, they will be pretested 
during FGDs with parents and GPs will be asked to 
provide input during outreach visits. Patient booklets 
would be developed together with a medical illustrator 
and could include information on viral versus bacterial 
infections, how to manage symptoms without antibiotics, 
how ABR develops and how to use antibiotics responsibly. 
The booklet will be distributed to a number of people 
from various backgrounds prior to large-scale printing in 
order to receive feedback on readability, attractiveness 
and user-friendliness and subsequently revised accord-
ingly. Posters and booklets will be made available at all 
clinics of participating GPs, and booklets will be used 
during patient consultations.
Delayed antibiotic prescription
Delayed antibiotic prescribing refers to a scenario where 
a doctor prescribes an antibiotic course on the condition 
that they should only be taken if symptoms persist or dete-
riorate after a given time period (generally between 48 
and 72 hours). A systematic review showed that delayed 
antibiotic prescribing results in marked reductions in 
antibiotic use and no significant differences in reconsul-
tation or complication rates.59 Although some national 
guidelines recommend delayed prescribing, its uptake 
in clinical practice remains low.60 61 The motivation 
behind its use varies from managing diagnostic uncer-
tainty and avoiding conflicts with patients (particularly 
those who tend to put pressure on doctors to prescribe), 
to a tool for patient education and to promote shared 
decision making.61 62 Some prescribers, however, feel 
uncomfortable shifting clinical responsibility onto their 
patients.61
Should Maltese GPs seem receptive to this prescription 
method, a delayed antibiotic prescription pad will be 
developed and distributed to GPs for use during consulta-
tions where a delayed prescription is deemed appropriate 
by the GP.
Delivery of educational sessions
A recent review of interventions to improve antibiotic 
use for RTIs showed that educational sessions, although 
laborious, seem more effective than audit and feedback 
and distribution of written patient information.17 Educa-
tional sessions can include: information on the core 
principles of prudent antibiotic use, introduction to new 
tools (such as guidelines), diagnostic skills training and 
patient communication techniques.31 A few studies have 
shown that sessions incorporating these topics can lead 
to sustained improvements in antibiotic use that last over 
2–4 years.63 64 The extent of the impact in other studies 
has generally been quite modest.58 65–68
Educational sessions will form a core part in the planned 
intervention and will be delivered in accordance with GP 
preferences. Topics will likely include those mentioned 
above as well as any other topics addressing specific needs 
identified during the formative research phase. In order 
to ease attendance, sessions will be delivered face-to-face 
but also streamed live and recorded for those unable to 
attend in person. Recorded sessions and all relevant mate-
rials will be uploaded to Ping Pong, the online learning 
platform used at Karolinska Institutet.
Process indicators
Several process indicator data will be collected throughout 
the intervention period, which will also help assess compli-
ance with the intervention protocol. Table 2 summarises a 
few indicators according to the intervention components 
previously described.
Postintervention phase: intervention evaluation
Outcome parameters
Primary outcome
The antibiotic prescribing rate for all patients with acute 
respiratory tract complaints, with the exception of pneu-
monia cases which will be excluded entirely.
Secondary outcomes
Secondary outcomes include the:
i. proportion of diagnosis-specific antibiotic 
prescription, specifically for the common cold, acute 
pharyngitis, acute sinusitis, acute bronchitis, acute 
tonsillitis, acute otitis media, allergy and influenza 
ii. proportion of symptomatic relief medication 
prescribed 
iii. change in GPs’ stage-of-change
iv. change in GPs’ behavioural intention to prescribe 
antibiotics.
In order to evaluate the effect of the intervention on 
GPs’ antibiotic prescribing, their intention to prescribe 
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Table 2 Process indicators collected during intervention period
Intervention components
Implementation outcomes
(process indicators) Data collection methods
  Antibiotic prescribing 
guidelines
 ► No. of guidelines distributed
 ► Frequency of reference to guidelines
 ► Usefulness of guidelines in practice
 ► Surveillance/monitoring
 ► Survey (postintervention)
  Posters  ► No. of posters printed
 ► No. of posters disseminated, per GP
 ► No. of posters displayed in clinics
 ► No. of QR code log-ins
 ► Surveillance/monitoring
 ► Logs
 ► Survey (postintervention)
  Booklets  ► No. of booklets printed
 ► No. of booklets disseminated, per GP
 ► No. of QR code log-ins
 ► Surveillance/monitoring
 ► Logs
 ► Survey (postintervention)
  Delayed antibiotic 
prescription pads
 ► No. of pads printed
 ► No. of pads disseminated, per GP
 ► No. of delayed antibiotic prescriptions issued
 ► No. of QR code log-ins
 ► Surveillance/monitoring
 ► Logs
 ► Collection of issued prescriptions
 ► Survey (postintervention)
  Educational sessions  ► No. of sessions held
 ►% attendance to sessions
 ►% attendance to sessions, by mode (face-to-
face, online (live), online (recorded))
 ► Satisfaction with session content and delivery
 ► Surveillance/monitoring
 ► Feedback questionnaires
 ► Survey (postintervention)
GP, general practitioner; QR, quick response.
antibiotics and stage-of-change, two sub-studies are 
planned and are described below.
Change in GPs’ intention to prescribe antibiotics and their 
readiness for change (substudy VI)
Following the completion of the intervention phase, all 
participating GPs will be asked to complete the same two 
questionnaires outlined in substudy IV with the aim of 
measuring the change in their intention to prescribe anti-
biotics and readiness for behaviour change postinterven-
tion. Apart from descriptive and comparative statistics, 
the plan is to analyse paired data using Wilcoxon signed-
rank test.
Change in GP’s antibiotic prescribing postintervention (substudy 
VII)
Following participation in the intervention phase, GPs 
will complete another year of surveillance using iden-
tical tools and methods used in substudy III. Apart from 
analysing the change in diagnosis-specific antibiotic 
prescribing patterns for respiratory tract complaints 
postintervention, the impact of the SM intervention 
on GPs’ antibiotic prescribing will also be evaluated. As 
before, GPs will also receive 3 monthly feedback reports 
(individual and aggregated). Descriptive statistics will 
be used to describe all variables collected through the 
surveillance. The 1 year antibiotic prescribing patterns as 
well as diagnosis-specific antibiotic prescribing rates and 
characteristics will also be reported. Finally, the change 
in antibiotic prescribing preintervention and postinter-
vention will be evaluated using interrupted time series 
analysis with segmented regression. Data will be clustered 
at GP level.
study status
The project was initiated in August 2014 and is ongoing. 
The preintervention phase ran from August 2014 to April 
2016. The intervention phase has just come to comple-
tion. The project is now in the postintervention phase.
EthIcs And dIssEMInAtIon
Ethical considerations
Each component of the project received ethical approval 
from the University of Malta’s Research Ethics Committee 
when needed.
Several ethical issues have been considered. For all 
substudies, participants received verbal information 
about the study’s purpose and their role as participants, 
in addition to information letters and informed consent. 
Participants were told that participation is voluntary and 
that they are free to withdraw without consequences. 
For the qualitative substudies, permission was requested 
to record the sessions. For the surveillance and inter-
vention components, no information gathered risks 
compromising the patient’s identity; no names and iden-
tifiable variables were collected. Nonetheless, standard 
data management protocols will be employed to ensure 
data safety. All data will be stored in a safe location and 
made confidential through the use of unique identifier 
codes kept in a separate file and accessible only to one 
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team member. Moreover, no identifiable material will be 
published publicly.
There are no anticipated risks associated with partic-
ipation apart from the time required to participate. 
We believe, rather, that informants could benefit from 
being given the opportunity to self-reflect on their own 
antibiotic use. In exchange for participation, GPs and 
pharmacists received certificates, allowing them to earn 
Continuing Professional Development (CPD) points from 
their respective colleges. Furthermore, GPs participating 
in surveillance received 3 monthly feedback reports (indi-
vidual and overall). Overall feedback is presented in an 
aggregate manner and does not include any GP or patient 
information that may compromise their identity.
dissemination plan
We plan to present our results at leading international 
and national conferences. We also plan to publish results 
in peer-reviewed scientific journals and disseminate them 
locally through local professional organisations. We 
intend to share our ultimate findings to the National Anti-
biotic Committee, which reports directly to the Superin-
tendent of Public Health of Malta.
dIscussIon
ABR respects no borders. It is a global problem with 
increasing magnitude, and it is critical that this escalating 
situation is addressed promptly. Although not a simple 
task, especially due to underlying cultural dimensions,32 36 
strategic behaviour change initiatives to promote prudent 
antibiotic use and prescribing are urgently required30 
and are attainable, as shown by other European coun-
tries.32 There is a need to propose simple solutions that 
consider local cultures and can be scaled up to become 
self-sustainable.35
To our knowledge, this community intervention is 
unique in Malta. It is the first to establish a community 
surveillance system and employ SM techniques to design, 
deliver and evaluate the effectiveness of a behaviour 
change intervention to improve antibiotic prescribing. 
As mentioned earlier, although SM techniques are prom-
ising to promote sustained behaviour change among 
selected groups,30 its utilisation for the prevention and 
control of communicable diseases in Europe has thus far 
been limited.44
Changing antibiotic prescribing behaviour is complex 
and requires multifaceted interventions.5 This study 
uses various approaches in an attempt to change GPs’ 
prescribing behaviour, generating evidence towards the 
effectiveness of tailored, multifaceted SM interventions 
in this field. It will allow us to gain insight into GPs’ 
diagnosis-specific antibiotic prescribing practices over 
time which, in Malta, has been hard to achieve so far. 
Should this intervention successfully decrease antibiotic 
prescribing rates, it may be scaled up locally and trans-
ferred to similar settings at a very low cost.
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APPENDIX II: IMPLEMENTATION OF THE MALTESE ANTIBIOTIC 
STEWARDSHIP PROGRAMME IN THE COMMUNITY (MASPIC) 
As mentioned in Chapter 3, the formative studies included in this thesis informed the design, 
development and implementation of a multi-faceted SM intervention targeting GPs’ specific 
needs. Described below is a short summary of the components delivered during the six-month 
intervention that ran between October 2016 and March 2017. 
Waiting room posters 
Four waiting room posters (Appendix III) were developed and pre-tested before implementa-
tion. During the six-month intervention, GPs were requested to put up all the four posters in 
patient waiting areas to serve as an educational tool. 
Patient booklets 
Patient booklets were developed in collaboration with a medical illustrator to drive across 
important messages on the correct use of antibiotics and to impart knowledge about the dif-
ferences between bacteria and viruses as well as self-care. These booklets were handed out to 
patients during one-to-one consultations with GPs by the GPs themselves. GPs were also 
encouraged to use the booklets as an educational tool. The booklets were double-sided to 
include both an English and a Maltese version. The English version can be found in Appen-
dix IV. 
Delayed antibiotic prescription pads 
Standardised DAP pads (Appendix V) were first developed by the Maltese National Antibi-
otic Committee and then adapted based on our pre-intervention findings. Patient information 
regarding the purpose of the DAP, what symptoms to look out for, and how to engage in self-
care were also added to the reverse side of the prescription. 
Updated national antibiotic guidelines 
Hard and soft copies of the updated national antibiotic guidelines were provided to all partic-
ipating GPs for their reference. This was combined with an educational session (see below) 
delivered to GPs as part of a series of educational sessions. 
Educational package 
Four interactive evening sessions were delivered to GPs over the six-month intervention peri-
od. The modules were delivered by four different lecturers and GPs were able to attend both 
in person and virtually through an online education platform specifically designed for the 
intervention. Sessions were also recorded to allow for later viewing if GPs were unavailable 
to attend in person on the day of the lecture. Topics included: (i) Antibiotic use and resistance 
from a global and local perspective – options for action, (ii) Introduction to the latest national 
antibiotic prescribing guidelines, (iii) The core principles of prudent antibiotic prescribing – 
appropriate antibiotic indications, dosages, choice and duration, and (iv) Effective patient 
communication – communication skills training and shared decision-making. 
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APPENDIX III: INTERVENTION MATERIALS – WAITING ROOM POSTERS 
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APPENDIX IV: INTERVENTION MATERIALS – PATIENT BOOKLET (ENGLISH VERSION) 
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APPENDIX V: INTERVENTION MATERIALS – DELAYED ANTIBIOTIC PRESCRIPTION PAD 
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APPENDIX VI: INTERVIEW GUIDE [PAPERS I & II] 
 
1) May you briefly tell me something about your work as a general practitioner? 
2) How do you look upon the role of antibiotics in medicine? 
3) How do you look upon antibiotic use and resistance in Malta (from a local and national 
level)? 
a. What factors do you think are contributing to this resistance in Malta? 
4) What do you understand by the term ‘unnecessary antibiotic prescribing’?  
5) Have you heard about ‘delayed antibiotic prescribing’? 
a. What do you understand by ‘delayed antibiotic prescribing’? 
b. What are your views on ‘delayed antibiotic prescribing’? 
6) What are your general thoughts on the antibiotic prescribing practices of other Maltese 
GPs? 
7) What are your views on the ‘drug rep culture’ in Malta? 
 
So now I would like you to reflect upon the last time you prescribed antibiotics and another 
time when you did not prescribe antibiotics for a respiratory tract infection. I would like you 
to respond to some related questions, keeping those scenarios in mind. 
 
8) What are your views on antibiotic prescribing for respiratory tract infections? 
a. Please describe your experience with antibiotic prescribing for respiratory tract 
infections. 
b. Please give me some examples of specific situations in which you prescribed or 
did not prescribe antibiotics for respiratory tract infections. 
c. How do you select which antibiotic to prescribe? 
9) What kind of information do you provide your patients who present with a respiratory 
tract infection? 
a. How do you look upon your role as an educator? 
10) Which factors do you think influence the way you prescribe antibiotics? 
11) How do you feel your patients impact your antibiotic prescribing? 
12) How do you feel the pharmaceutical industry/medical reps impact your antibiotic 
prescribing? 
13) What are your thoughts on near-patient testing to aid in identifying infections? 
a. Do you make use of near-patient tests yourself? 
14) What do you do if someone in your own family/a close relative has a respiratory tract 
infection? 
15) What do you think are your specific needs in terms of antibiotic prescribing for 
respiratory tract infections? 
16) Is there anything else that you would like to add? 
 
Thank you for your time and valuable insight into this topic!
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APPENDIX VII: GP DEMOGRAPHICS SHEET [PAPERS I-IV] 
  Date: ____________ 
 GP demographics 
1)  Date of birth:  
2)  Sex: □ Male □ Female 
3) Country of birth:  
4) Home address:  
5) E-mail address:  
6a) Telephone no.:  6b) Mobile no.:  
7) Country where you obtained your medical undergraduate degree:  
8 ) Years of practice as a doctor (in total):  
9a) Year of specialisation in family medicine (if specialised): 
 
9b) Did you full under the ‘grandfather clause’? □ Yes            □ No 
9c) Are you currently a trainee? □ Yes            □ No 
10) Years of practice as a GP:  
11) How much do you currently work? □ Part-time    □ Full-time 
12) Approximately how many patients do you meet daily?  
Thank you for your input!
13) Health sector of practice (please tick all relevant options): Type of Sector Location 
□ Public sector □ Healthcare centre 
□ Home visits 
□ Solo practice □ Private clinic 
□ Pharmacy clinic 
□ Home visits 
□ Group practice □ Private clinic 
□ Pharmacy clinic 
□ Home visits 
□ Company doctor 
14)  Areas within which you conduct home visits (if applicable): 
15) Please write the addresses of your practice/s and tick your main clinic of practice: 
(N.B. If you work in a pharmacy, please include the name of that pharmacy) 
Address Main clinic of practice (please tick) 
 □ 
 □ 
 □ 
GP code: [for office use only]: 
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APPENDIX VIII: SURVEILLANCE DATA COLLECTION FORM [PAPERS III & IV] 
 
